## Oral Candidiasis in High-Risk Patients as the Initial Mar Immunodeficiency Syndrome

New England Journal of Medicine 311, 354-358 DOI: 10.1056/nejm198408093110602

**Citation Report** 

#	Article	IF	CITATIONS
1	EPIDEMIOLOGY OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)1. Epidemiologic Reviews, 1985, 7, 1-21.	3.5	68
2	Acquired Immune Deficiency Syndrome: A Perspective for the Medical Practitioner. Medical Clinics of North America, 1985, 69, 637-655.	2.5	4
3	Ultrastructural Markers in Circulating Lymphocytes of Subjects at Risk for AIDS. American Journal of Clinical Pathology, 1985, 84, 603-609.	0.7	37
4	The Acquired Immunodeficiency Syndrome in a Cohort of Homosexual Men. Annals of Internal Medicine, 1985, 103, 210.	3.9	207
5	Oral candidiasis: Forerunner of acquired immunodeficiency syndrome (AIDS)?. Oral Surgery, Oral Medicine, and Oral Pathology, 1985, 60, 532-534.	0.6	38
6	Cytomegalovirus presence and salivary composition in acquired immunodeficiency syndrome. Oral Surgery, Oral Medicine, and Oral Pathology, 1985, 60, 372-376.	0.6	44
7	Gastrointestinal Aspects of the Acquired Immunodeficiency Syndrome. Digestive Diseases, 1985, 3, 197-209.	1.9	5
8	Seroepidemiology of Human T-Lymphotropic Virus Type III Among Homosexual Men with the Acquired Immunodeficiency Syndrome or Generalized Lymphadenopathy and Among Asymptomatic Controls in Boston. Annals of Internal Medicine, 1985, 102, 334.	3.9	58
9	Immunopathology Associated with Human Lymphotropic Retroviruses. Pathology and Immunopathology Research, 1985, 4, 216-226.	0.8	4
10	Acquired Immune Deficiency Syndrome (AIDS): disease characteristics and oral manifestations. Journal of the American Dental Association, 1985, 111, 258-261.	1.5	15
11	Gastroenterology and Hepatology. JAMA - Journal of the American Medical Association, 1985, 254, 2267.	7.4	0
12	Patients at Risk for AIDS-Related Opportunistic Infections. New England Journal of Medicine, 1985, 313, 1504-1510.	27.0	197
13	Unexplained Lymphadenopathy in Homosexual Men. JAMA - Journal of the American Medical Association, 1985, 254, 930.	7.4	39
14	Unusual cutaneous lesions associated with acquired immunodeficiency syndrome. Journal of the American Academy of Dermatology, 1985, 13, 845-852.	1.2	215
15	DIVERSITY OF CLINICAL SPECTRUM OF HTLV-III INFECTION. Lancet, The, 1985, 325, 301-304.	13.7	46
16	Non-Hodgkin's lymphoma, HTLV-III/LAV, and HTLV-III/LAV antibody in the wife of a man with transfusion-acquired AIDS. American Journal of Medicine, 1986, 81, 898-900.	1.5	3
17	Herpes zoster: A possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals. Journal of the American Academy of Dermatology, 1986, 14, 1023-1028.	1.2	173
18	Fungal Infections in Patients with AIDS and AIDS-related Complex. Scandinavian Journal of Infectious Diseases, 1986, 18, 179-192.	1.5	150

ATION RE

<u> </u>			-		
(†17	ΓΑΤΙ	ION	I K	FP	ORT

#	Article	IF	CITATIONS
19	POORLY ENCAPSULATED < i> CRYPTOCOCCUS NEOFORMANS  FROM PATIENTS WITH AIDS. II. CORRELATION OF CAPSULE SIZE OBSERVED DIRECTLY IN CEREBROSPINAL FLUID WITH THAT AFTER ANIMAL PASSAGE. AIDS Research, 1986, 2, 219-225.	0.5	21
20	ORAL MANIFESTATIONS IN INPATIENTS WITH AIDS OR AIDS-RELATED COMPLEX. Lancet, The, 1986, 328, 288.	13.7	41
21	Prognostically significant classification of immune changes in AIDS with Kaposi's sarcoma. Blood, 1986, 67, 666-671.	1.4	76
22	T Cell Proliferation and Ablation. Chemical Immunology and Allergy, 1986, 37, 224-243.	1.7	0
23	Carcinoembryonic Antigen. Annals of Internal Medicine, 1986, 104, 888.	3.9	3
24	The Likelihood Ratio and Diagnostic Tests. Annals of Internal Medicine, 1986, 104, 888.	3.9	4
25	Searching the Medical Literature. Annals of Internal Medicine, 1986, 104, 889.	3.9	0
26	Chronic Obstructive Pulmonary Disease and Carbohydrate Feedings. Annals of Internal Medicine, 1986, 104, 889.	3.9	1
27	Epstein-Barr Virus Infection and Hodgkin's Disease. Annals of Internal Medicine, 1986, 104, 890.	3.9	1
28	The Acquired Immunodeficiency Syndrome and Cryptococcosis. Annals of Internal Medicine, 1986, 104, 891.	3.9	9
29	Hairy Leukoplakia and the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine, 1986, 104, 892.	3.9	29
30	Diabetic Diarrhea and Somatostatin. Annals of Internal Medicine, 1986, 104, 894.	3.9	30
31	Mallory-Weiss Tear with Colonic Lavage. Annals of Internal Medicine, 1986, 104, 894.	3.9	19
32	Cardiac Risk in Noncardiac Geriatric Surgery. Annals of Internal Medicine, 1986, 104, 887.	3.9	3
33	Fraud and Irresponsible Authorship. Annals of Internal Medicine, 1986, 104, 886.	3.9	1
34	Calcium, Race, and Hypertension. Annals of Internal Medicine, 1986, 104, 892.	3.9	0
35	Metoclopramide Infusion with a Disposable Portable Pump. Annals of Internal Medicine, 1986, 104, 896.	3.9	22
36	Expression of Activation Antigen on Lymphocytes in the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine, 1986, 104, 890.	3.9	6

#	Article	IF	CITATIONS
37	Rapid Reversal of Myxedema Madness with Triiodothyronine. Annals of Internal Medicine, 1986, 104, 893.	3.9	12
38	Nitroprusside Toxicity and Low-Dose Infusion. Annals of Internal Medicine, 1986, 104, 895.	3.9	12
39	Agranulocytosis and Ranitidine. Annals of Internal Medicine, 1986, 104, 896.	3.9	29
40	Piroxicam and Pancreatitis. Annals of Internal Medicine, 1986, 104, 895.	3.9	15
41	Bone Disease in Alcohol Abuse. Annals of Internal Medicine, 1986, 104, 893.	3.9	3
42	The Clinical Approach to the Male Homosexual Patient. Medical Clinics of North America, 1986, 70, 499-535.	2.5	15
43	Clinical Approach to Intestinal Infections in Homosexual Men. Medical Clinics of North America, 1986, 70, 611-634.	2.5	18
44	The Acquired Immunodeficiency Syndrome: Epidemiology and Risk Factors for Transmission. Medical Clinics of North America, 1986, 70, 635-649.	2.5	11
45	Kaposi's Sarcoma and AIDS. Medical Clinics of North America, 1986, 70, 139-154.	2.5	19
46	The Clinical Challenges of AIDS and HIV Infection. Journal of Law, Medicine, and Ethics, 1986, 14, 281-289.	0.6	4
47	Thrombocytopenia in homosexual men. American Journal of Hematology, 1986, 21, 243-247.	4.1	52
48	Acquired immunodeficiency syndrome. Journal of Surgical Oncology, 1986, 2, 53-71.	1.4	1
49	Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome. International Journal of Dermatology, 1986, 25, 337-350.	1.0	90
50	Oral hairy leukoplakia: ultrastructural features. Journal of Oral Pathology and Medicine, 1986, 15, 493-499.	2.7	57
51	Dermatologic Manifestations Of Internal Cancer. Ca-A Cancer Journal for Clinicians, 1986, 36, 130-148.	329.8	23
52	Oral condyloma planus (hairy leukoplakia) among homosexual men: A clinicopathologic study of thirty-six cases. Oral Surgery, Oral Medicine, and Oral Pathology, 1986, 61, 249-255.	0.6	83
53	An update on the acquired immunodeficiency syndrome (AIDS). Diseases of the Colon and Rectum, 1986, 29, 60-64.	1.3	23
54	Pulmonary cytology of the acquired immune deficiency syndrome: An analysis of 36 cases. Diagnostic Cytopathology, 1986, 2, 181-186.	1.0	14

		EPORT	
#	Article	IF	CITATIONS
55	Giant esophageal ulcers in patients with AIDS-related complex. Dysphagia, 1986, 1, 84-87.	1.8	9
56	Persistent, painful ulcerations of the hard palate and buccal mucosa. Journal of the American Dental Association, 1986, 112, 877-878.	1.5	2
57	AIDS and AIDS-related complex: oral manifestations and treatment/Surgery and orthodontic treatment for unerupted teeth/Closing anterior diastemas with cosmetic bonding. Journal of the American Dental Association, 1986, 113, 585-597.	1.5	23
58	Infections of the Gastrointestinal Tract in the Immunocompromised Patient. Annual Review of Medicine, 1986, 37, 271-281.	12.2	38
59	Leukopenia and Anergy as Predictors of AIDS. JAMA - Journal of the American Medical Association, 1986, 255, 1289.	7.4	0
60	Tinea Faciale Mimicking Seborrheic Dermatitis in a Patient with AIDS. New England Journal of Medicine, 1986, 314, 315-316.	27.0	39
61	POORLY ENCAPSULATED <i>CRYPTOCOCCUS NEOFORMANS </i> FROM PATIENTS WITH AIDS. I: PRELIMINARY OBSERVATIONS. AIDS Research, 1986, 2, 211-218.	0.5	34
62	Gastroenterology and Hepatology. JAMA - Journal of the American Medical Association, 1986, 256, 2088.	7.4	0
63	Oral Hairy Leukoplakia. Archives of Dermatology, 1987, 123, 624.	1.4	21
64	Treatment of Patients With Acquired Immunodeficiency Syndrome and Associated Manifestations. JAMA - Journal of the American Medical Association, 1987, 257, 1367.	7.4	84
65	Relation of Oral Hairy Leukoplakia to Infection with the Human Immunodeficiency Virus and the Risk of Developing AIDS. Journal of Infectious Diseases, 1987, 155, 475-481.	4.0	263
66	Clinical, Immunologic, and Serologic Findings in Men at Risk for Acquired Immunodeficiency Syndrome. JAMA - Journal of the American Medical Association, 1987, 257, 326.	7.4	66
67	Predictors of AIDS in Homosexual Men. New England Journal of Medicine, 1987, 317, 245-246.	27.0	1
68	Oral Candida albicans in HIV Infection. Scandinavian Journal of Infectious Diseases, 1987, 19, 291-295.	1.5	111
69	AIDS and infection control in dental practice: dentists' attitudes, knowledge, and behavior. Journal of the American Dental Association, 1987, 114, 311-314.	1.5	98
70	Chronic Vaginal Candidiasis in Women With Human Immunodeficiency Virus Infection. JAMA - Journal of the American Medical Association, 1987, 257, 3105.	7.4	135
71	Hairy Leukoplakia. Archives of Dermatology, 1987, 123, 585.	1.4	22
72	Secretory IgA Antibodies to Human Immunodeficiency Virus in the Parotid Saliva of Patients with AIDS and AIDS-Related Complex. Journal of Infectious Diseases, 1987, 155, 793-796.	4.0	69

#	Article	IF	CITATIONS
73	Infection with the Human Immunodeficiency Virus: Clinical Manifestations and Their Relationship to Immune Deficiency. Annals of Internal Medicine, 1987, 107, 474.	3.9	195
74	AIDS update: oral findings, diagnosis, and precautions. Journal of the American Dental Association, 1987, 115, 559-563.	1.5	27
75	Management of Infectious and Immunological Complications of Acquired Immunodeficiency Syndrome (AIDS). Drugs, 1987, 33, 66-84.	10.9	15
76	Pediatric Human Immunodeficiency Virus Infection and its Cutaneous Manifestations. Pediatric Dermatology, 1987, 4, 67-74.	0.9	42
77	Acquired Immunodeficiency Syndrome (AIDS). Survey of Ophthalmology, 1987, 31, 384-410.	4.0	137
78	Pneumocystis carinii pneumonia in infants givenadrenocorticotropic hormone for infantile spasms. Journal of Pediatrics, 1987, 110, 901-903.	1.8	12
79	Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. Journal of the American Academy of Dermatology, 1987, 17, 210-220.	1.2	242
80	Dermatologic findings related to human immunodeficiency virus infection in high-risk individuals. Journal of the American Academy of Dermatology, 1987, 17, 951-961.	1.2	48
81	Dermatologic findings associated with human immunodeficiency virus infection. Journal of the American Academy of Dermatology, 1987, 17, 746-751.	1.2	122
82	Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). Journal of the American Academy of Dermatology, 1987, 16, 485-506.	1.2	305
83	AIDS and the oral cavity. The HIV-infection: Virology, etiology, origin, immunology, precautions and clinical observations in 110 patients. International Journal of Oral and Maxillofacial Surgery, 1987, 16, 129-153.	1.5	93
84	AIDS and the oral cavity. International Journal of Oral and Maxillofacial Surgery, 1987, 16, 1-14.	1.5	95
85	RISK OF AIDS AFTER HERPES ZOSTER. Lancet, The, 1987, 329, 728-731.	13.7	170
86	The AIDS epidemic and the drug substance abuse patient. Journal of Substance Abuse Treatment, 1987, 4, 127-136.	2.8	6
87	Mucocutaneous findings in acquired immunodeficiency syndrome/AIDS-related complex patients. Journal of the American Academy of Dermatology, 1987, 16, 888-889.	1.2	7
88	Mucous membrane manifestations of the acquired immunodeficiency syndrome. Clinics in Dermatology, 1987, 5, 182-189.	1.6	1
89	Oral Candidiasis. Dermatologic Clinics, 1987, 5, 651-662.	1.7	16
90	Oral Mucosal Manifestations of AIDS. Dermatologic Clinics, 1987, 5, 733-737.	1.7	39

#	Article	IF	CITATIONS
91	In situ hybridization to detect Epstein-Barr virus DNA in oral tissues of HIV-infected patients. Virchows Archiv A, Pathological Anatomy and Histopathology, 1987, 412, 127-133.	1.4	66
92	Intestinal plasma cell alterations in acquired immunodeficiency syndrome. Digestive Diseases and Sciences, 1987, 32, 129-138.	2.3	95
93	Oral findings in patients with acquired immunodeficiency syndrome. Oral Surgery, Oral Medicine, and Oral Pathology, 1987, 64, 50-56.	0.6	195
94	Oral manifestations of disseminated Cryptococcus neoformans in a patient with acquired immunodeficiency syndrome. Oral Surgery, Oral Medicine, and Oral Pathology, 1987, 64, 454-459.	0.6	69
95	Oral hairy leukoplakia in three hemophiliacs with human immunodeficiency virus infection. Oral Surgery, Oral Medicine, and Oral Pathology, 1987, 63, 437-440.	0.6	47
96	Radiology of nonneoplastic gastrointestinal disorders in acquired immune deficiency syndrome. Seminars in Roentgenology, 1987, 22, 31-41.	0.6	18
97	Absence of Langerhans Cells in Oral Hairy Leukoplakia, an AIDS-Associated Lesion. Journal of Investigative Dermatology, 1987, 89, 178-182.	0.7	96
98	Skin Manifestations in AIDS, HIV Infection, and AIDS-Related Complex. International Journal of Dermatology, 1987, 26, 267-272.	1.0	45
99	Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome Update 1987. International Journal of Dermatology, 1987, 26, 615-630.	1.0	88
100	AIDS and the Dermatologist. International Journal of Dermatology, 1987, 26, 1-7.	1.0	18
101	MURINE CANDIDIASIS: III. HOST INFLAMMATORY RESPONSES ARE REGULATED IN PART BY CLASS I MHC GENES. International Journal of Immunogenetics, 1987, 14, 317-321.	1.2	10
102	Acquired immunodeficiency syndrome: a perspective*. Australian Dental Journal, 1987, 32, 22-27.	1.5	3
103	Abnormal antibody responses in patients with persistent generalized lymphadenopathy. Journal of Clinical Immunology, 1988, 8, 57-63.	3.8	40
104	White nails in AIDS/ARC due to Trichophyton rubrum infection. Clinical and Experimental Dermatology, 1988, 13, 24-25.	1.3	45
105	Murine candidiasis: Strain dependence of host responses after immunization. Immunology and Cell Biology, 1988, 66, 231-237.	2.3	22
106	AIDS and Dental Practice. Journal of Public Health Dentistry, 1988, 48, 68-73.	1.2	37
107	Anorectal and colonic disease and the immunocompromised host. Diseases of the Colon and Rectum, 1988, 31, 971-976.	1.3	10
108	Oral candidal infection as a sign of HIV infection in homosexual men. Oral Surgery, Oral Medicine, and Oral Pathology, 1988, 65, 36-40.	0.6	48

#	Article	IF	CITATIONS
109	Oral hairy leukoplakia among HIV-positive intravenous drug abusers: A clinicopathologic and ultrastructural study. Oral Surgery, Oral Medicine, and Oral Pathology, 1988, 65, 421-426.	0.6	70
110	A comparison of the inhibition of blastospore viability and germ-tube development in Candida albicans by histidine peptides and ketoconazole. Archives of Oral Biology, 1988, 33, 567-573.	1.8	33
111	Disseminated herpes zoster in patients with human immunodeficiency virus infection. American Journal of Medicine, 1988, 84, 1076-1080.	1.5	83
112	HIV-1 and HIV-2 Double Infection In Greece. Annals of Internal Medicine, 1988, 108, 155.	3.9	8
113	Cutaneous manifestations of human immunodeficiency virus in Lusaka, Zambia. Journal of the American Academy of Dermatology, 1988, 19, 451-457.	1.2	105
114	Mucocutaneous manifestations in patients infected with human immunodeficiency virus. Journal of the American Academy of Dermatology, 1988, 19, 290-297.	1.2	40
115	CANDIDA AND AIDS: EVIDENCE FOR PROTECTIVE ANTIBODY. Lancet, The, 1988, 332, 263-266.	13.7	112
116	PRESENT DAY PRACTICE IN INFANT FEEDING. Lancet, The, 1988, 331, 975-976.	13.7	3
117	OROFACIAL MANIFESTATIONS OF HIV INFECTION. Lancet, The, 1988, 331, 976-977.	13.7	2
118	Oral manifestations of AIDS: a study of 84 patients. Journal of the American Dental Association, 1988, 116, 863-866.	1.5	30
119	Oral candidiasis and AIDS. Journal of the American Dental Association, 1988, 116, 818-820.	1.5	1
120	Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. Medical Mycology, 1988, 26, 67-71.	0.7	115
121	HIV disease and the gastroenterologist Gut, 1988, 29, 1497-1505.	12.1	20
122	T4+ Cell Production of Interferon Gamma and the Clinical Spectrum of Patients at Risk for and With Acquired Immunodeficiency Syndrome. Archives of Internal Medicine, 1988, 148, 1613.	3.8	35
123	A larger spectrum of severe HIV-1related disease in intravenous drug users in New York City. Science, 1988, 242, 916-919.	12.6	200
124	Unusual Extrapulmonary Manifestations of Deep Mycoses. Seminars in Respiratory and Critical Care Medicine, 1988, 9, 440-441.	2.1	0
125	Bronchoesophageal Manifestations of Acquired Immunodeficiency Syndrome. Annals of Otology, Rhinology and Laryngology, 1988, 97, 530-533.	1.1	7
126	The Natural History of Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1988, 158, 1360-1367.	4.0	172

# 127	ARTICLE Numbers of CD4+ Cells and the Levels of Core Antigens of and Antibodies to the Human Immunodeficiency Virus as Predictors of AIDS Among Seropositive Homosexual Men. Journal of	IF 4.0	Citations 207
128	Infectious Diseases, 1988, 158, 615-622. Treatment of Infections Associated with Human Immunodeficiency Virus. New England Journal of Medicine, 1988, 318, 1439-1448.	27.0	216
129	Importance of assessing risk behavior for AIDS. Postgraduate Medicine, 1988, 83, 138-152.	2.0	1
130	Esophageal candidiasis. Postgraduate Medicine, 1988, 84, 193-205.	2.0	37
131	THE SYDNEY AIDS PROJECT: DEVELOPMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME IN A GROUP OF HIV SEROPOSITIVE HOMOSEXUAL MEN. Australian and New Zealand Journal of Medicine, 1988, 18, 8-15.	0.5	56
132	Standard and Computed Tomography in the Evaluation of Chest Neoplasms. Annals of Internal Medicine, 1988, 108, 160.	3.9	1
133	Meta-Analysis in Clinical Research. Annals of Internal Medicine, 1988, 108, 158.	3.9	1
134	Inability to Predict Diagnosis in Febrile Intravenous Drug Abusers. Annals of Internal Medicine, 1988, 108, 153.	3.9	0
135	AIDS in Black Patients. Dermatologic Clinics, 1988, 6, 435-442.	1.7	1
136	Occult Carbon Monoxide Poisoning. Annals of Internal Medicine, 1988, 108, 150.	3.9	1
137	Routine Testing for Chlamydial Cervical Infections. Annals of Internal Medicine, 1988, 108, 153.	3.9	0
138	Classification Systems for Human Immunodeficiency Virus (HIV) Infection. Annals of Internal Medicine, 1988, 108, 155.	3.9	4
139	Essential Hypertension in Men and Women. Annals of Internal Medicine, 1988, 108, 148.	3.9	1
140	Hazards of the Swan-Ganz Catheter. Annals of Internal Medicine, 1988, 108, 151.	3.9	6
141	Laboratory Use: Persisting Attitudes Implicit in a National Examination. Annals of Internal Medicine, 1988, 108, 158.	3.9	0
142	Thrombotic Thrombocytopenic Purpura and Herpes Zoster Infection. Annals of Internal Medicine, 1988, 108, 154.	3.9	15
143	Sex Bias and Coronary Bypass Surgery. Annals of Internal Medicine, 1988, 108, 149.	3.9	5
144	Screening for Primary Hyperparathyroidism. Annals of Internal Medicine, 1988, 108, 151.	3.9	2

	CIAI	ION REPORT	
#	Article	IF	CITATIONS
145	Protein S and the Nephrotic Syndrome. Annals of Internal Medicine, 1988, 108, 152.	3.9	2
146	Acquired Immunodeficiency Syndrome (AIDS) as an Occupational Disease. Annals of Internal Medicine, 1988, 108, 156.	3.9	3
147	Cost Containment and Hypertension. Annals of Internal Medicine, 1988, 108, 148.	3.9	4
148	Plasmapheresis and Pulse Cyclophosphamide in Systemic Lupus Erythematosus. Annals of Internal Medicine, 1988, 108, 152.	3.9	12
149	Evaluating the Risk of Gallbladder Cancer. Annals of Internal Medicine, 1988, 108, 157.	3.9	1
150	Cryptococcal Bursitis. Annals of Internal Medicine, 1988, 108, 154.	3.9	10
151	Assessing Adverse Drug Experiences. Annals of Internal Medicine, 1988, 108, 160.	3.9	3
152	Fungal infections of the immunocompromised host: clinical and laboratory aspects. Clinical Microbiology Reviews, 1988, 1, 349-364.	13.6	114
153	Human Immunodeficiency Virus Infection. Dermatologic Clinics, 1989, 7, 369-386.	1.7	4
154	Development and in vitro Evaluation of an Intra-oral Controlled-release Delivery System for Chlorhexidine. Journal of Dental Research, 1989, 68, 1285-1288.	5.2	22
155	Gastrointestinal and systemic candidosis in immunocompromised mice. Medical Mycology, 1989, 27, 363-380.	0.7	59
156	Diagnosis and management of HIV-associated periodontal lesions. Journal of the American Dental Association, 1989, 119, 25S-34S.	1.5	61
157	Fungal and mycobacterial infections in patients infected with the human immunodeficiency virus. Journal of Antimicrobial Chemotherapy, 1989, 23, 107-125.	3.0	38
158	A New Prognostic Staging System for the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1989, 320, 1388-1393.	27.0	127
159	<i>Candida</i> Cell Wall Mannan: A Polysaccharide with Diverse Immunologic Properties. Critical Reviews in Microbiology, 1989, 17, 33-51.	6.1	81
160	Pulmonary Infections in the Acquired Immune Deficiency Syndrome. Seminars in Respiratory and Critical Care Medicine, 1989, 10, 1-11.	2.1	4
161	Oral mucosal lesions: Association with the presence of antibodies to the human immunodeficiency virus. Oral Surgery, Oral Medicine, and Oral Pathology, 1989, 68, 37-43.	0.6	62
162	Acquired immune deficiency syndrome presenting as a palatal perforation. Oral Surgery, Oral Medicine, and Oral Pathology, 1989, 67, 313-318.	0.6	36

#	Article	IF	CITATIONS
163	Orofacial manifestations of a group of British patients infected with HIV-1. Journal of Oral Pathology and Medicine, 1989, 18, 47-48.	2.7	67
164	High levels of oral yeasts in early HIV-1 infection. Journal of Oral Pathology and Medicine, 1989, 18, 520-524.	2.7	56
165	Oral candidiasis and human immunodeficiency virus infection. Journal of Oral Pathology and Medicine, 1989, 18, 554-564.	2.7	171
166	Clinical, histologic and scanning electron microscopic study of the development of chronic candidiasis of the rat tongue. Journal of Oral Pathology and Medicine, 1989, 18, 352-359.	2.7	15
167	Low prevalence of oral mucosal lesions in HIV-1 seropositive African women. Journal of Oral Pathology and Medicine, 1989, 18, 416-418.	2.7	30
168	Cloning of a DNA sequence encoding a major fragment of the 47 kilodalton stress protein homologue ofCandida albicans. FEMS Microbiology Letters, 1989, 60, 25-30.	1.8	67
169	The microbiology of HIV-associated periodontal lesions. Journal of Clinical Periodontology, 1989, 16, 636-642.	4.9	87
170	AIDS and HIV-1 Infection: Clinical Entities in Geriatric Dentistry1. Gerodontology, 1989, 8, 27-32.	2.0	3
171	Skin disease in haemophiliacs with and without antibodies to the human immunodeficiency virus (HIV): further evidence of altered disease behaviour in different risk groups?. British Journal of Dermatology, 1989, 120, 795-799.	1.5	8
172	Fungal infections in the immunocompromised host. Diagnostic Microbiology and Infectious Disease, 1989, 12, 221-228.	1.8	58
173	Mucocutaneous manifestations of HIV infection. Clinics in Dermatology, 1989, 7, 56-64.	1.6	2
174	Disseminated Histoplasmosis in a Danish Patient with AIDS. Scandinavian Journal of Infectious Diseases, 1989, 21, 573-577.	1.5	21
175	AIDS and the gastroenterologist. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 547-561.	2.8	2
176	Dermatitis of the Face, Yellow Toe Nail Changes, Hairy Leukoplakia and Oral Candidiasis Are Clinical Indicators of Progression to AIDS/Opportunistic Infection in Patients with HIV Infection. Scandinavian Journal of Infectious Diseases, 1989, 21, 497-505.	1.5	19
177	Antifungal combination therapy in localized candidosis. Mycoses, 1990, 33, 353-358.	4.0	7
178	Oral candidosis in HIVâ€infected patients. Prognostic value and correlation with immunological parameters. Mycoses, 1990, 33, 421-425.	4.0	15
179	Increased Candida Demonstrated in Subgingival Plaques of Aids Patients by Microwave-Accelerated Silver Staining. Materials Research Society Symposia Proceedings, 1990, 189, 355.	0.1	1
180	Image Analysis Method to Count Silver-Stained Candida in Aids Patients' Subgingival Plaques. Materials Research Society Symposia Proceedings, 1990, 189, 371.	0.1	3

#	Article	IF	CITATIONS
181	Oral Findings in HIV-Infected Patients Attending A Department of Internal Medicine: The Contribution of Intraoral Examination Towards the Clinical Management of HIV Disease. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	3
182	The role of pH in salivary histidine-rich polypeptide antifungal germ tube inhibitory activity. Oral Microbiology and Immunology, 1990, 5, 336-339.	2.8	24
183	Ectopic Geographic Tongue and AIDS. International Journal of Dermatology, 1990, 29, 113-116.	1.0	7
184	Epidemiology, clinical features and prognostic value of HIV-1 related oral lesions. Journal of Oral Pathology and Medicine, 1990, 19, 477-481.	2.7	105
185	Oral manifestations of AIDS in a heterosexual population in a Zaire hospital. Journal of Oral Pathology and Medicine, 1990, 19, 232-234.	2.7	68
186	Prevalence of dental caries, gingivitis, and oral hygiene in hospitalized AIDS cases in Kinshasa, Zaire. Journal of Oral Pathology and Medicine, 1990, 19, 271-272.	2.7	17
187	Antigens and immune responses in <i>Candida albicans</i> infection. Immunology and Cell Biology, 1990, 68, 1-13.	2.3	23
188	Oral lesions in Mexican HIV-infected patients. Journal of Oral Pathology and Medicine, 1990, 19, 482-485.	2.7	35
189	1 Clinical picture and management. Best Practice and Research: Clinical Haematology, 1990, 3, 1-35.	1.1	1
190	8 The treatment of HIV disease. Best Practice and Research: Clinical Haematology, 1990, 3, 153-175.	1.1	0
191	AIDS: an overview. Bailliere's Clinical Gastroenterology, 1990, 4, 259-289.	0.9	3
192	Oral manifestations of HIV disease. Bailliere's Clinical Gastroenterology, 1990, 4, 315-337.	0.9	2
193	Upper gastrointestinal tract infections in AIDS. Bailliere's Clinical Gastroenterology, 1990, 4, 339-359.	0.9	5
194	Oral melanotic macules in patients infected with human immunodeficiency virus. Oral Surgery, Oral Medicine, and Oral Pathology, 1990, 70, 748-755.	0.6	54
195	Oral candidiasis and hairy leukoplakia correlate with HIV infection in Tanzania. Oral Surgery, Oral Medicine, and Oral Pathology, 1990, 69, 591-596.	0.6	61
196	HIV-associated periodontitis complicated by necrotizing stomatitis. Oral Surgery, Oral Medicine, and Oral Pathology, 1990, 69, 351-355.	0.6	78
197	Prevalence of oral lesions among HIV-infected intravenous drug abusers and other risk groups. Oral Surgery, Oral Medicine, and Oral Pathology, 1990, 69, 169-173.	0.6	97
198	Epidemiology of digestive tract mycoses in immunocompromised patients ? A review. European Journal of Epidemiology, 1990, 6, 363-370.	5.7	6

#	Article	IF	CITATIONS
199	Alimentary tract cytopathology in human immunodeficiency virus infection: A review of experience in los angeles. Diagnostic Cytopathology, 1990, 6, 409-420.	1.0	9
200	An Animal Model for Oropharyngeal, Esophageal and Gastric Candidosis. Mycoses, 1990, 33, 7-19.	4.0	42
201	Development of AIDS in a cohort of HIVâ€seropositive homosexual men in Australia. Medical Journal of Australia, 1990, 153, 260-265.	1.7	18
202	Fluconazole for Life-Threatening Fungal Infections in Patients Who Cannot Be Treated with Conventional Antifungal Agents. Clinical Infectious Diseases, 1990, 12, S349-S363.	5.8	83
203	Factors predisposing to oral yeast infections. Acta Odontologica Scandinavica, 1990, 48, 71-74.	1.6	66
204	Granulocyte-Macrophage Colony-Stimulating Factor Augments Human Monocyte Fungicidal Activity for Candida albicans. Journal of Infectious Diseases, 1990, 161, 999-1005.	4.0	134
205	The Impact of Oral Examination on the Centers for Disease Control Classification of Subjects With Human Immunodeficiency Virus Infection. Archives of Internal Medicine, 1990, 150, 1259.	3.8	13
206	Candida albicans in Patients with the Acquired Immunodeficiency Syndrome: Absence of a Novel or Hypervirulent Strain. Journal of Infectious Diseases, 1990, 162, 513-518.	4.0	109
207	The natural history of human immunodeficiency virus infection: a five year study in a London cohort of homosexual men Sexually Transmitted Infections, 1990, 66, 238-243.	1.9	5
208	Current Trends in Candida albicans Research. Advances in Microbial Physiology, 1990, 30, 53-88.	2.4	32
209	Nutritional Aspects of AIDS. Annual Review of Nutrition, 1990, 10, 475-501.	10.1	38
210	Role of tumor necrosis factor and colony-stimulating factors in phagocyte function against Candida albicans. Diagnostic Microbiology and Infectious Disease, 1990, 13, 383-386.	1.8	26
211	Cutaneous manifestations of HIV infection other than Kaposi's sarcoma: Clinical and histologic aspects. Journal of the American Academy of Dermatology, 1990, 22, 1260-1269.	1.2	54
212	Prognostic markers for AIDS. Annals of Epidemiology, 1990, 1, 129-139.	1.9	5
213	Fungal Infections in HIV Patients. Annals of the New York Academy of Sciences, 1990, 616, 461-468.	3.8	6
214	Studies of the Subgingival Microflora in Patients With Acquired Immunodeficiency Syndrome. Journal of Periodontology, 1990, 61, 699-704.	3.4	145
215	Successfully treated candida sinusitis in an AIDS patient. Journal of Cranio-Maxillo-Facial Surgery, 1990, 18, 175-178.	1.7	23
216	Pulmonary Infectious Complications of Human Immunodeficiency Virus Infection: Part II. The American Review of Respiratory Disease, 1990, 141, 1582-1598.	2.9	154

#	Article	IF	CITATIONS
217	Predicting progression to AIDS: Combined usefulness of CD4 lymphocyte counts and p24 antigenemia. American Journal of Medicine, 1990, 89, 706-712.	1.5	86
218	Hierarchical pattern of mucosal candida infections in HIV-seropositive women. American Journal of Medicine, 1990, 89, 142-146.	1.5	221
219	AIDS and the gastroenterologist. Journal of Gastroenterology and Hepatology (Australia), 1990, 5, 45-62.	2.8	8
220	Approach to gastrointestinal manifestations in infants and children with HIV infection. Journal of Pediatrics, 1991, 119, S34-S40.	1.8	8
221	Fungal and mycobacterial skin infections. Clinics in Dermatology, 1991, 9, 65-69.	1.6	6
222	Serologic and immunologic markers in the course of HIV-1 infection. Clinics in Dermatology, 1991, 9, 1-11.	1.6	9
223	DNA probe detection of periodontal pathogens in HIV-associated periodontal lesions. Oral Microbiology and Immunology, 1991, 6, 34-40.	2.8	60
224	Production of granulocyte-macrophage colony-stimulating factor by large granular lymphocytes stimulated with Candida albicans: role in activation of human neutrophil function. Blood, 1991, 77, 2259-2265.	1.4	57
225	Natural History of Human Immunodeficiency Virus Infection. Dermatologic Clinics, 1991, 9, 429-441.	1.7	5
226	Oral Manifestations of HIV Infection. Dermatologic Clinics, 1991, 9, 517-522.	1.7	14
227	HIV and Periodontal Health. Journal of the American Dental Association, 1991, 122, 49-54.	1.5	63
228	Response to Treatment with the Leukocyte-derived Immunomodulator IMREG-1 in Immunocompromised Patients with AIDS-related Complex. Annals of Internal Medicine, 1991, 115, 84.	3.9	21
229	Identification of oral yeasts by polyacrylamide gel electrophoresis. Oral Microbiology and Immunology, 1991, 6, 187-190.	2.8	17
230	Nebulized Pentamidine for the Prevention of <italic>Pneumocystis carinii</italic> Pneumonia in AIDS Patients: Experience of 173 Patients and a Review of the Literature. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	3
231	Oral manifestations of HIV infection and their management. I. More common lesions. Oral Surgery, Oral Medicine, and Oral Pathology, 1991, 71, 158-166.	0.6	75
232	Treatment of refractory oral candidiasis with fluconazole. Oral Surgery, Oral Medicine, and Oral Pathology, 1991, 71, 42-44.	0.6	26
233	Major aphthous-like ulcers in patients with AIDS. Oral Surgery, Oral Medicine, and Oral Pathology, 1991, 71, 68-72.	0.6	62

#	Article	IF	CITATIONS
235	Lectin-carbohydrate interactions in immunoregulation. International Journal of Biochemistry & Cell Biology, 1991, 23, 631-640.	0.5	23
236	Prevalence of dermatophytes and yeasts (Candida spp., Malassezia furfur) in HIV patients. Mycopathologia, 1991, 114, 103-107.	3.1	14
237	Vitreous fluorophotometric recordings in HIV infection. International Ophthalmology, 1991, 15, 37-40.	1.4	7
238	The Growing Problem of Mycoses in Patients Infected with the Human Immunodeficiency Virus. Clinical Infectious Diseases, 1991, 13, 480-486.	5.8	138
239	Acquired Immunity to Systemic Candidiasis in Immunodeficient Mice. Journal of Infectious Diseases, 1991, 164, 936-943.	4.0	62
240	Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrobial Agents and Chemotherapy, 1991, 35, 2302-2305.	3.2	150
241	Periodontal Disease in Heterosexuals With Acquired Immunodeficiency Syndrome. Journal of Periodontology, 1991, 62, 535-540.	3.4	40
242	Safety and efficacy of fluconazole treatment for Candida oesophagitis in AIDS. Postgraduate Medical Journal, 1991, 67, 548-552.	1.8	11
243	Management of the Oral Lesions of HIV Infection. Journal of the American Dental Association, 1991, 122, 26-32.	1.5	24
244	Human Immunodeficiency Virus Infection and the Skin. Archives of Internal Medicine, 1991, 151, 1295.	3.8	34
245	The prophylaxis of fungal infections. Journal of Antimicrobial Chemotherapy, 1991, 28, 97-103.	3.0	30
246	Risk Stratification of Ambulatory Patients Suspected of Pneumocystis Pneumonia. Archives of Internal Medicine, 1991, 151, 105.	3.8	20
247	Anti-Candida resistance in the mouse brain and effect of intracerebral administration of interleukin 1. Journal of General Microbiology, 1991, 137, 1799-1804.	2.3	37
248	Clinical signs and laboratory markers in predicting progression to AIDS in HIV–1 infected patients. Scandinavian Journal of Infectious Diseases, 1991, 23, 443-449.	1.5	42
249	Clinical Manifestations and Predictors of Disease Progression in Drug Users with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1992, 327, 1697-1703.	27.0	303
250	Cutaneous Findings Associated with HIV Disease Including AIDS: Experience from Sub Saharan Africa. Tropical Doctor, 1992, 22, 35-41.	0.5	13
251	Course of Primary Candidiasis in T Cell-Depleted Mice Infected with Attenuated Variant Cells. Journal of Infectious Diseases, 1992, 166, 1384-1392.	4.0	54
252	Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation. Journal of General Microbiology, 1992, 138, 1901-1911.	2.3	79

			PORT	
# 253	ARTICLE Fungal infections in AIDS patients. Medical Mycology, 1992, 30, 19-28.		IF 0.7	CITATIONS
253	rungar mections in AIDS patients. Medical Mycology, 1992, 50, 19-28.		0.7	104
254	CD4 Lymphocyte Decline and Survival in Human Immunodeficiency Virus Infection. AID Human Retroviruses, 1992, 8, 2039-2047.	S Research and	1.1	10
255	VA Oral HIV Surveillance Program: Understanding the Disease. Journal of the American Association, 1992, 123, 57-62.	Dental	1.5	4
256	Antifungal activities of salivary histidine-rich polypeptides against Candida albicans and yeast isolates. Oral Microbiology and Immunology, 1992, 7, 51-52.	other oral	2.8	26
257	Bacterial and Fungal Infections. Medical Clinics of North America, 1992, 76, 173-203.		2.5	43
258	Gastrointestinal Infections in AIDS. Annals of Internal Medicine, 1992, 116, 63-77.		3.9	177
259	Sinusitis in HIV-1 infection. American Journal of Medicine, 1992, 93, 157-162.		1.5	84
260	<i>Candida</i> Infections in AIDS Patients. International Journal of STD and AIDS, 1992	e, 3, 157-160.	1.1	15
261	HIV-Related Infections of the Oral Cavity. Critical Reviews in Oral Biology and Medicine,	1992, 3, 207-231.	4.4	22
262	Salivary anti-candidal assays. Oral Microbiology and Immunology, 1992, 7, 38-43.		2.8	15
263	Oral Candidiasis. Clinics in Geriatric Medicine, 1992, 8, 513-528.		2.6	23
264	The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albican cavity of HIV-infected subjects. European Journal of Epidemiology, 1992, 8, 362-367.	s from the oral	5.7	37
265	Antigen-specific cytolysis of infected cells in murine candidiasis. European Journal of Ep 1992, 8, 368-376.	idemiology,	5.7	5
266	Models of interactions between HIV and other pathogens. Journal of Theoretical Biology 69-86.	y, 1992, 155,	1.7	78
267	Longitudinal study of parotid saliva in HIV-1 infection. Journal of Oral Pathology and Me 21, 209-213.	edicine, 1992,	2.7	90
268	HIV-associated oral lesions; immunologic, virologic and salivary parameters. Journal of C Pathology and Medicine, 1992, 21, 295-298.	Dral	2.7	52
269	The Role of BCG/PPD-Activated Macrophages in Resistance against Systemic Candidiasi Scandinavian Journal of Immunology, 1992, 36, 713-720.	s in Mice.	2.7	143
270	The role of hsp90 in fungal infection. Trends in Immunology, 1992, 13, 345-348.		7.5	80

#	Article	IF	CITATIONS
271	Evaluation of prognosis and survival of the HIV-infected patient. Oral Surgery, Oral Medicine, and Oral Pathology, 1992, 74, 386-392.	0.6	12
272	Correlation of subclinical candidal colonization of the dorsal tongue surface with the Walter Reed staging scheme for patients infected with HIV-1. Oral Surgery, Oral Medicine, and Oral Pathology, 1992, 73, 47-51.	0.6	11
273	Salivary gland involvement in HIV-1 infection. Oral Surgery, Oral Medicine, and Oral Pathology, 1992, 73, 168-170.	0.6	21
274	Oral mycoses in HIV infection. Oral Surgery, Oral Medicine, and Oral Pathology, 1992, 73, 171-180.	0.6	232
275	Oral manifestations of HIV infection in children. Oral Surgery, Oral Medicine, and Oral Pathology, 1992, 73, 187-192.	0.6	50
276	Oral diseases in HIV-1 infection. Dysphagia, 1992, 7, 126-137.	1.8	19
277	Asymptomatic oral Candida albicans carriage in HIV-infection: frequency and predisposing factors. Journal of Oral Pathology and Medicine, 1993, 22, 57-59.	2.7	36
278	Leukocyte dysfunction in oral mucous membrane diseases. Journal of Oral Pathology and Medicine, 1993, 22, 120-125.	2.7	19
279	Detection of anti-HIV antibodies in saliva. Journal of Oral Pathology and Medicine, 1993, 22, 153-156.	2.7	15
280	Oral carriage of candida in healthy and HIV-seropositive persons. Oral Surgery, Oral Medicine, and Oral Pathology, 1993, 76, 570-572.	0.6	74
281	Synthetic chemotherapeutic drugs for the treatment of mycoses (review). Pharmaceutical Chemistry Journal, 1993, 27, 227-241.	0.8	1
282	A simple clinical staging system that predicts progression to AIDS using CD4 count, oral thrush, and night sweats. Journal of General Internal Medicine, 1993, 8, 5-9.	2.6	51
283	Resistance of SCID Mice to Candida albicans Administered Intravenously or Colonizing the Gut: Role of Polymorphonuclear Leukocytes and Macrophages. Journal of Infectious Diseases, 1993, 167, 912-919.	4.0	112
284	Progress in the understanding of HIV infection: An overview. Journal of the American Academy of Dermatology, 1993, 29, 1-21.	1.2	12
285	Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet, The, 1993, 342, 143-146.	13.7	119
286	Oral manifestations in HIV-infected patients: Diagnosis and management. Journal of the American Academy of Dermatology, 1993, 29, 749-760.	1.2	41
287	Preincubation of Candida albicans strains with amphotericin B reduces tumor necrosis factor alpha and interleukin-6 release by human monocytes. Antimicrobial Agents and Chemotherapy, 1993, 37, 1958-1961.	3.2	14
288	Identification of a 65-kDa Mannoprotein as a Main Target of Human CellMediated Immune Response to Candida albicans. Journal of Infectious Diseases, 1993, 168, 427-435.	4.0	71

#	Article	IF	Citations
289	Mechanism of Intracellular Candidacidal Activity Mediated by Calcium Ionophore in Human Alveolar Macrophages. American Journal of Respiratory Cell and Molecular Biology, 1993, 9, 19-25.	2.9	18
290	Sinusitis and Atopy in Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1993, 167, 283-290.	4.0	74
291	Mucosal and Systemic T Helper Cell Function after Intragastric Colonization of Adult Mice with Candida albicans. Journal of Infectious Diseases, 1993, 168, 1449-1457.	4.0	71
292	Guidelines for the Design and Conduct of AIDS Clinical Trials. Clinical Infectious Diseases, 1993, 16, 816-822.	5.8	4
293	Morphotypes of oral isolates of <i>Candida albicans</i> from patients infected with the human immunodeficiency virus. Medical Mycology, 1993, 31, 289-297.	0.7	9
294	Oral Candida in HIV Infection and AIDS: New Perspectives/New Approaches. Critical Reviews in Microbiology, 1993, 19, 61-82.	6.1	138
295	Effects of Stem Cell Factor and Granulocyte Colony-Stimulating Factor on Granulocyte Recovery and Candida albicans Infection in Granulocytopenic Mice. Journal of Infectious Diseases, 1993, 168, 1444-1448.	4.0	16
296	Comparison of Clinical Symptoms of Human Immunodeficiency Virus Disease Between Intravenous Drug Users and Homosexual Men. Archives of Internal Medicine, 1993, 153, 1806.	3.8	26
297	Predicting the Outcomes of Human Immunodeficiency Virus Infection. Archives of Internal Medicine, 1993, 153, 2749.	3.8	14
298	Oral Candidiasis Is Associated with Low Levels of Parotid Calprotectin in Individuals with Infection Due to Human Immunodeficiency Virus. Clinical Infectious Diseases, 1993, 16, 301-302.	5.8	33
299	Antifungal Prophylaxis in Immunocompromised Hosts. Annals of Pharmacotherapy, 1993, 27, 53-60.	1.9	29
300	Acquired resistance and persistence of Candida albicans following oral candidiasis in the mouse: a model of the carrier state in humans. Oral Microbiology and Immunology, 1993, 8, 313-318.	2.8	29
301	The yeast Candida albicans has a clonal mode of reproduction in a population of infected human immunodeficiency virus-positive patients Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9456-9459.	7.1	185
302	Skin manifestations of human immunodeficiency virus (HIV): Part 1. Infectious manifestations. Journal of Osteopathic Medicine, 1993, 93, 106-106.	0.8	0
303	Impact of the Acquired Immunodeficiency Syndrome Epidemic on the Practice of Laryngology. Annals of Otology, Rhinology and Laryngology, 1993, 102, 3-24.	1.1	5
304	Pathogenesis, Natural History, and Classification of HIV Infection. Critical Care Clinics, 1993, 9, 13-29.	2.6	2
305	Fungi and fungal infections of the skin. , 1993, , 232-263.		9
306	Infectious Esophagitis. Gastrointestinal Endoscopy Clinics of North America, 1994, 4, 713-729.	1.4	30

#	Article	IF	CITATIONS
307	The effects of human immunodeficiency virus infection on macrophage phagocytosis of Candida. Oral Microbiology and Immunology, 1994, 9, 55-59.	2.8	3
308	Häfigkeit von HIV-assoziierten Erkrankungen im Kopf-Hals-Bereich. Oto-rhino-laryngologia Nova, 1994, 4, 194-198.	0.0	0
309	Necrotizing Ulcerative Periodontitis: A Marker for Immune Deterioration and a Predictor for the Diagnosis of AIDS. Journal of Periodontology, 1994, 65, 393-397.	3.4	128
310	Antifungal Activity of Recombinant Human Macrophage Colony-Stimulating Factor in Models of Acute and Chronic Candidiasis in the Rat. Journal of Infectious Diseases, 1994, 169, 369-374.	4.0	39
311	Candida albicans expresses a fibronectin receptor antigenically related to Â5Â1 integrin. Microbiology (United Kingdom), 1994, 140, 2971-2979.	1.8	53
312	Clinical significance and outcome of Candida vaginitis in human immunodeficiency seropositive women. Journal of Obstetrics and Gynaecology, 1994, 14, s131-s135.	0.9	0
313	Macrophage Activation by N-Acetyl-cysteine in COPD Patients. Chest, 1994, 105, 806-811.	0.8	26
314	A scanning electronmicroscopy investigation of the structure of colonies of different morphologies produced by phenotypic switching of Candida albicans. Journal of Medical Microbiology, 1994, 40, 416-423.	1.8	40
315	The Role Of Phagocytic Cells In Resistance To Disseminated Candidiasis In Granulocytopenic Mice. Journal of Infectious Diseases, 1994, 170, 900-905.	4.0	66
316	Candidacidal Activity of Macrophages from Immunocompetent and Congenitally Immunodeficient Mice. Journal of Infectious Diseases, 1994, 170, 180-188.	4.0	33
317	Humoral and Cellular Immune Responses to Enolase after Alimentary Tract Colonization or Intravenous Immunization with Candida albicans. Journal of Infectious Diseases, 1994, 170, 390-395.	4.0	47
318	Clinical and microbiological characteristics of symptomatic vulvovaginal candidiasis in HIV-seropositive women Sexually Transmitted Infections, 1994, 70, 268-272.	1.9	29
319	Azole-Resistant Candida albicans: Report of Two Cases of Resistance to Fluconazole and Review. Clinical Infectious Diseases, 1994, 19, 687-692.	5.8	63
320	Mucocutaneous diseases in drug addicts with or without HIV infection. A case-control study. Infection, 1994, 22, 77-80.	4.7	2
321	Median rhomboid glossitis. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 78, 36-40.	0.6	14
322	Immunologic status in patients infected with HIV with oral candidiasis and hairy leukoplakia. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 78, 41-46.	0.6	51
323	Oral manifestations of HIV infection in homosexual men and intravenous drug users. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 78, 163-174.	0.6	80
324	Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 77, 344-349.	0.6	203

#	Article	IF	CITATIONS
325	Major aphthous ulcers in patients with HIV disease. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 77, 116-120.	0.6	57
326	Candida-associated palatal papillary hyperplasia in HIV infection. Journal of Oral Pathology and Medicine, 1994, 23, 403-405.	2.7	26
327	Oral candidiasis and immune status of HIV-infected patients. Journal of Oral Pathology and Medicine, 1994, 23, 140-143.	2.7	70
328	Periodontal diseases in patients infected by human immunodeficiency virus. Periodontology 2000, 1994, 6, 50-67.	13.4	38
329	Building the Capacity for the Response of the Dental Profession to the Global HIV Pandemic: A Case Study in International Collaboration. Journal of Public Health Dentistry, 1994, 54, 234-237.	1.2	1
330	HIV infection and the dentist. 2. The diagnosis and management of gingivitis and periodontitis. Australian Dental Journal, 1994, 39, 73-76.	1.5	4
331	Pattern of cytokine gene expression in brains of mice protected by picolinic acid against lethal intracerebral infection with Candida albicans. Journal of Neuroimmunology, 1994, 52, 205-213.	2.3	23
332	Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. American Journal of Medicine, 1994, 97, 339-346.	1.5	329
333	Management of common superficial fungal infections in patients with AIDS. Journal of the American Academy of Dermatology, 1994, 31, S60-S63.	1.2	62
334	The role of cell-mediated immunity in candidiasis. Trends in Microbiology, 1994, 2, 202-206.	7.7	102
335	Mechanisms of cell-mediated immunity in fungal infection. Medical Mycology, 1994, 32, 123-131.	0.7	13
336	Candida and Oral Candidosis: A Review. Critical Reviews in Oral Biology and Medicine, 1994, 5, 125-157.	4.4	271
337	Mycoses in AIDS patients. Medical Mycology, 1994, 32, 65-77.	0.7	51
338	Differential pattern of infection and i immune response during experimental oral candidiasis in BALB/c and DBA/2 (Hâ€2 <sup>d</sup> ) mice. Oral Microbiology and Immunology, 1994, 9, 88-94.	2.8	59
339	HIV Infection of monocyte-derived macrophages in vitro reduces phagocytosis of Candida albicans. Journal of Leukocyte Biology, 1994, 56, 318-327.	3.3	66
341	Potential Application of Human Interferon-α in Microbial Infections of the Oral Cavity. Journal of Interferon and Cytokine Research, 1995, 15, 1047-1051.	1.2	8
342	Validity of contourâ€clamped homogeneous electric field electrophoresis as a typing system for <i>Candida albicans</i> . Mycoses, 1995, 38, 29-36.	4.0	15
343	Synergy of fluconazole with macrophages for antifungal activity againstCandida albicans. Mycopathologia, 1995, 132, 123-128.	3.1	9

#	Article	IF	CITATIONS
344	Biotypes of oral Candida albicans isolates in human immunodeficiency virus-infected patients from diverse geographic locations. Journal of Oral Pathology and Medicine, 1995, 24, 32-36.	2.7	21
345	Avirulence ofCandida albicansauxotrophic mutants in a rat model of oropharyngeal candidiasis. FEMS Microbiology Letters, 1995, 126, 177-180.	1.8	38
346	The effects of colony stimulating factors on human monocyte cell function. International Journal of Immunopharmacology, 1995, 17, 385-392.	1.1	33
347	T helper cell dichotomy toCandida albicans: Implications for pathology, therapy, and vaccine design. Immunologic Research, 1995, 14, 148-162.	2.9	29
348	Clinical Parameters Associated with Recalcitrant Oral Candidosis in HIV Infection: A Preliminary Study. International Journal of STD and AIDS, 1995, 6, 204-207.	1.1	3
349	Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV. Journal of Antimicrobial Chemotherapy, 1995, 36, 109-118.	3.0	23
350	Genetic Variability of Candida albicans in HIV Infection. Microbial Ecology in Health and Disease, 1995, 8, 63-70.	3.5	6
351	Fluconazole for Refractory Oropharyngeal Candidiasis in AIDS Patients. AIDS Patient Care and STDs, 1995, 9, 56-59.	0.1	2
352	Beneficial Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Fungicidal Activity of Polymorphonuclear Leukocytes from Patients with AIDS. Journal of Infectious Diseases, 1995, 171, 1448-1454.	4.0	80
353	Nitric Oxide Enhances Resistance of SCID Mice to Mucosal Candidiasis. Journal of Infectious Diseases, 1995, 172, 192-198.	4.0	52
354	T Helper Cell Type 1 (Th1)- and Th2-like Responses Are Present in Mice with Gastric Candidiasis but Protective Immunity Is Associated with Th1 Development. Journal of Infectious Diseases, 1995, 171, 1279-1288.	4.0	128
355	DNA Subtypes and Fluconazole Susceptibilities of Candida albicans Isolates from the Oral Cavities of Patients with AIDS. Clinical Infectious Diseases, 1995, 20, 634-640.	5.8	61
356	Biomolecular events involved in the establishment of brain anticandidal resistance. Journal of Neuroimmunology, 1996, 64, 9-17.	2.3	14
357	Guidelines of care for superficial mycotic infections of the skin: Mucocutaneous candidiasis. Journal of the American Academy of Dermatology, 1996, 34, 110-115.	1.2	19
358	Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. Medical Mycology, 1996, 34, 337-339.	0.7	60
359	Emerging Disease Issues and Fungal Pathogens Associated with HIV Infection. Emerging Infectious Diseases, 1996, 2, 109-116.	4.3	102
360	Biological Role of Th Cell Subsets in Candidiasis. Chemical Immunology and Allergy, 1996, 63, 115-137.	1.7	33
361	Enhanced oxidative killing of azole-resistant Candida glabrata strains with ERG11 deletion. Antimicrobial Agents and Chemotherapy, 1996, 40, 1717-1719.	3.2	22

#	Article	IF	Citations
362	Immunopathogenesis of recurrent vulvovaginal candidiasis. Clinical Microbiology Reviews, 1996, 9, 335-348.	13.6	260
363	Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrobial Agents and Chemotherapy, 1996, 40, 1317-1320.	3.2	28
364	Detection and Significance of Fluconazole Resistance in Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected Patients. Journal of Infectious Diseases, 1996, 174, 821-827.	4.0	114
365	Infection by <i>Candida albicans</i> inhibits apoptosis of human monocytes and monocytic U937 cells. Journal of Leukocyte Biology, 1996, 60, 737-743.	3.3	27
366	Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 30-37.	2.9	52
367	Medical mycology. Mycological Research, 1996, 100, 1153-1162.	2.5	14
368	Synergy of human neutrophils with fluconazole in killing Candida species. Mycopathologia, 1996, 134, 115-120.	3.1	25
369	Prognostic value of oral candidosis and hairy leukoplakia in 111 Mexican HIV-infected patients. Journal of Oral Pathology and Medicine, 1996, 25, 206-211.	2.7	23
370	Oral manifestations associated with human immunodeficiency virus infection in a Spanish population. Journal of Oral Pathology and Medicine, 1996, 25, 523-527.	2.7	75
371	Human Immunodeficiency Virus—Related Oral Manifestations and Gender. Archives of Internal Medicine, 1996, 156, 2249.	3.8	44
372	A Murine Model of Candida glabrata Vaginitis. Journal of Infectious Diseases, 1996, 173, 425-431.	4.0	85
373	Candida albicans adherence to a human oesophageal cell line. Microbiology (United Kingdom), 1996, 142, 2741-2746.	1.8	26
374	Transfer of a Gene Encoding the Anticandidal Protein Histatin 3 to Salivary Glands. Human Gene Therapy, 1996, 7, 2255-2261.	2.7	75
375	Is Vulvovaginal Candidiasis an AIDS-Related Illness?. Clinical Infectious Diseases, 1996, 22, S124-S127.	5.8	55
376	Vaginalâ€Associated Immunity in Women with Recurrent Vulvovaginal Candidiasis: Evidence for Vaginal Th1â€Type Responses following Intravaginal Challenge withCandidaAntigen. Journal of Infectious Diseases, 1997, 176, 728-739.	4.0	80
377	Single-Organism Model of Host Defense against Infection: A Novel Immunotoxicologic Approach to Evaluate Immunomodulatory Drugs. Toxicologic Pathology, 1997, 25, 351-362.	1.8	23
378	Human Immunodeficiency Virus Type 1 gp41 Binds toCandida albicansvia Complement C3â€like Regions. Journal of Infectious Diseases, 1997, 176, 492-498.	4.0	19
379	A Randomized, Doubleâ€Blind Comparison of Itraconazole Oral Solution and Fluconazole Tablets in the Treatment of Esophageal Candidiasis. Journal of Infectious Diseases, 1997, 176, 227-232.	4.0	106

#	Article	IF	Citations
380	Less common oral lesions associated with HIV infection: Prevalence and classification. Oral Diseases, 1997, 3, S208-13.	3.0	32
381	Possible participation of polymorphonuclear cells stimulated by microbial immunomodulators in the dysregulated cytokine patterns of AIDS patients. Journal of Leukocyte Biology, 1997, 62, 60-66.	3.3	25
382	The social, economic and political impact of the global HIV/AIDS epidemic. Oral Diseases, 1997, 3, S7-12.	3.0	2
383	Selection and pathogenicity of <i>Candida albicans</i> in HIV infection. Oral Diseases, 1997, 3, S88-95.	3.0	23
384	Candidiasis. Aids, 1997, 11, 557-567.	2.2	205
385	Sentinels and signposts: The epidemiology and significance of the oral manifestations of HIV disease. Oral Diseases, 1997, 3, S13-7.	3.0	70
386	Initiation of T-Helper Cell Immunity to Candida albicans by IL-12: The Role of Neutrophils. , 1997, 68, 110-135.		67
387	Atypical strains of <i>Candida albicans</i> recovered from AIDS patients. Medical Mycology, 1997, 35, 115-121.	0.7	32
388	Oropharyngeal Candidiasis in Patients with AIDS: Randomized Comparison of Fluconazole Versus Nystatin Oral Suspensions. Clinical Infectious Diseases, 1997, 24, 1204-1207.	5.8	94
389	BACTERIAL INFECTIONS. Medical Clinics of North America, 1997, 81, 319-343.	2.5	26
390	ORAL MANIFESTATIONS OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION. Medical Clinics of North America, 1997, 81, 511-531.	2.5	5
391	FUNGAL INFECTIONS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME. Medical Clinics of North America, 1997, 81, 381-409.	2.5	66
392	Oral keratinocyte immune responses in HIV-associated candidiasis. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1997, 84, 372-380.	1.4	61
393	Oral manifestations of HIV disease: An update. Seminars in Cutaneous Medicine and Surgery, 1997, 16, 257-264.	1.6	7
394	Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clinical Therapeutics, 1997, 19, 471-480.	2.5	55
395	Efficacy of D0870 treatment of experimental Candida vaginitis. Antimicrobial Agents and Chemotherapy, 1997, 41, 1455-1459.	3.2	19
396	Quantitative cultures of <i>Candida</i> from mouthwash fluid in HIVâ€infected patients: a longitudinal study. Mycoses, 1997, 40, 377-380.	4.0	4
397	Oral candidiasis in HIV infection: predictive value and comparison of findings in injecting drug users and homosexual men. Journal of Oral Pathology and Medicine, 1997, 26, 237-243.	2.7	31

#	Article	IF	CITATIONS
398	Genotypic identification of sequentialCandida albicans isolates from AIDS patients by polymerase chain reaction techniques. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 601-605.	2.9	28
399	Responsiveness of human polymorphonuclear cells (PMNL) to stimulation by a mannoprotein fraction (MP-F2) of Candida albicans ; enhanced production of IL-6 and tumour necrosis factor-alpha (TNF-α) by MP-F2-stimulated PMNL from HIV-infected subjects. Clinical and Experimental Immunology, 1997, 107, 451-457.	2.6	21
400	Candida biotypes isolated from clinical specimens in Malaysia. Mycopathologia, 1998, 144, 135-140.	3.1	19
401	The relationship between salivary histatin levels and oral yeast carriage. Oral Microbiology and Immunology, 1998, 13, 181-187.	2.8	44
402	Crossâ€sectional study of oral Candida carriage in a human immunodeficiency virus (HIV)â€seropositive population: predisposing factors, epidemiology and antifungal susceptibility. Mycoses, 1998, 41, 203-211.	4.0	32
403	Adherence of <i>Staphylococcus aureus, Klebsiella pneumoniae</i> from healthy persons and HIV carriers, under the influence of Broncho Vaxom <i>in vitro</i> and ascorbic acid <i>in vivo</i> . Apmis, 1998, 106, 441-448.	2.0	7
404	Cellular immunity in recurrent vulvovaginal candidiasis. Clinical and Experimental Immunology, 1998, 111, 574-578.	2.6	48
405	Changing role of invasive aspergillosis in AIDS — a case control study. Journal of Infection, 1998, 37, 116-122.	3.3	18
406	Role of arachidonic acid metabolites in the action of a β adrenergic agonist on human monocyte phagocytosis. Prostaglandins Leukotrienes and Essential Fatty Acids, 1998, 58, 85-90.	2.2	29
407	Immunogenic and protective Candida albicans constituents. Research in Immunology, 1998, 149, 289-299.	0.9	25
408	Protective immunity in experimental Candida vaginitis. Research in Immunology, 1998, 149, 361-373.	0.9	29
409	UPDATE ON CUTANEOUS MANIFESTATIONS OF HIV INFECTION. Medical Clinics of North America, 1998, 82, 1033-1080.	2.5	35
410	A Doubleâ€Blind Comparison of Itraconazole Oral Solution and Fluconazole Capsules for the Treatment of Oropharyngeal Candidiasis in Patients with AIDS. Clinical Infectious Diseases, 1998, 26, 1368-1373.	5.8	68
411	Oral Lesions among Women Living with or at Risk for HIV Infection. American Journal of Medicine, 1998, 104, 559-564.	1.5	48
412	Clinical predictors of azole resistance, outcome and survival from oesophageal candidiasis in AIDS patients. International Journal of STD and AIDS, 1998, 9, 16-20.	1.1	1
413	Clinical predictors of azole resistance, outcome and survival from oesophageal candidiasis in AIDS patients. International Journal of STD and AIDS, 1998, 9, 16-20.	1.1	9
414	Recognition of Antigenic Clusters of Candida albicans by T Lymphocytes from Human Immunodeficiency Virus-Infected Persons. Journal of Infectious Diseases, 1998, 178, 488-496.	4.0	29
415	Human Immunodeficiency Virus Type 1 Envelope Protein gp120 Impairs Intracellular Antifungal Mechanisms in Human Monocytes. Journal of Infectious Diseases, 1998, 177, 347-354.	4.0	22

#	Article	IF	CITATIONS
416	Oral examination: a screening tool for HIV infection?. Sexually Transmitted Infections, 1998, 74, 345-348.	1.9	19
417	Vaginal Candidiasis: Review and Role of Local Mucosal Immunity. AIDS Patient Care and STDs, 1998, 12, 359-366.	2.5	21
418	Mucosal Candidal Colonization and Candidiasis in Women with or at Risk for Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 1998, 27, 1161-1167.	5.8	92
419	Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis [published erratum appears in J Antimicrob Chemother 1998 Sep;42(3):413]. Journal of Antimicrobial Chemotherapy, 1998, 41, 541-548.	3.0	38
420	Th1/Th2 Cytokine Expression in Saliva of HIV-Positive and HIV-Negative Individuals: A Pilot Study in HIV-Positive Individuals With Oropharyngeal Candidiasis. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 373-380.	0.3	81
421	Oropharyngeal Lesions in AIDS. Gastrointestinal Endoscopy Clinics of North America, 1998, 8, 783-807.	1.4	4
422	Activity of Voriconazole, a New Triazole, Combined with Neutrophils or Monocytes against <i>Candida albicans</i> : Effect of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor. Antimicrobial Agents and Chemotherapy, 1998, 42, 907-910.	3.2	59
423	Multiple Resistant Phenotypes of Candida albicans Coexist during Episodes of Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy, 1999, 43, 1621-1630.	3.2	93
424	Specific Microbial Colonizations in the Periodontal Sites of HIVâ€infected Subjects. Microbiology and Immunology, 1999, 43, 847-852.	1.4	26
425	Comparison of Clinical Manifestations of HIV Infection Among Women by Risk Group, CD4+ Cell Count, and HIV-1 Plasma Viral Load. Journal of Acquired Immune Deficiency Syndromes, 1999, 20, 448-454.	0.3	14
426	Evidence for αvβ3 and αvβ5 Integrinâ€like Vitronectin (VN) Receptors inCandida albicansand Their Involvement in Yeast Cell Adhesion to VN. Journal of Infectious Diseases, 1999, 180, 156-166.	4.0	41
427	Evolution of Vaginal Candida Species Recovered from Human Immunodeficiency Virusâ€Infected Women Receiving Fluconazole Prophylaxis: The Emergence of Candida glabrata?. Clinical Infectious Diseases, 1999, 28, 1025-1031.	5.8	55
428	Differential Susceptibility of Two Species of Macaques to Experimental Vaginal Candidiasis. Journal of Infectious Diseases, 1999, 180, 802-810.	4.0	57
429	Evidence that Members of the Secretory Aspartyl Proteinase Gene Family, in Particular <i>SAP2,</i> Are Virulence Factors for <i>Candida</i> Vaginitis. Journal of Infectious Diseases, 1999, 179, 201-208.	4.0	164
430	Denture Plaque and Adherence of Candida Albicans To Denture-Base Materials in Vivo and in Vitro. Critical Reviews in Oral Biology and Medicine, 1999, 10, 99-116.	4.4	256
431	Phagocytosis of <i>Candida albicans,</i> by concanavalin-A activated peritoneal macrophages. Medical Mycology, 1999, 37, 195-200.	0.7	11
432	Experimental Oropharyngeal and Gastrointestinal Candida Infection in Mice. , 1999, , 663-666.		0
433	Oropharyngeal candidosis in AIDS patients: an epidemiological study using restriction analysis ofCandida albicanstotal genomic DNA. Mycoses, 1999, 42, 41-46.	4.0	4

#	Article	IF	CITATIONS
434	PCR–restriction fragment length polymorphism (RFLP) analyses reveal both extensive clonality and local genetic differences inCandidaalbicans. Molecular Ecology, 1999, 8, 59-73.	3.9	80
435	Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology, 1999, 41, 227-234.	2.0	69
436	Strain-dependent migration of lymphocytes to the vaginal mucosa after peripheral immunization. Immunogenetics, 1999, 49, 973-980.	2.4	14
437	Increased severity of Candida vaginitis in BALB/c nu/nu mice versus the parent strain is not abrogated by adoptive transfer of T cell enriched lymphocytes. Journal of Reproductive Immunology, 1999, 45, 1-18.	1.9	33
438	Effect of fluconazole on the growth and adhesion of <i>Candida albicans</i> in the presence of antineoplastic agents. Journal of Basic Microbiology, 1999, 39, 305-310.	3.3	11
439	Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1999, 88, 573-580.	1.4	59
440	Dissimilar Attenuation of Candida albicans Virulence Properties by Human Immunodeficiency Virus Type 1 Protease Inhibitors. Immunobiology, 1999, 201, 133-144.	1.9	35
441	Dermatologic Manifestations in HIV-Infected Patients: A Primary Care Perspective. Mayo Clinic Proceedings, 1999, 74, 658-660.	3.0	20
442	Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. Aids, 2000, 14, 979-985.	2.2	78
443	Evidence for a unique expression of CD4 on murine vaginal CD4+ cells. Immunology, 2000, 100, 300-308.	4.4	10
444	Adherence in tissues of immunocompromised mice of a non-mycelium producing strain of Candida albicans. Mycoses, 2000, 43, 185-189.	4.0	2
445	Cytokine profiles in parotid saliva from HIV-1-infected individuals: changes associated with opportunistic infections in the oral cavity. Oral Microbiology and Immunology, 2000, 15, 74-81.	2.8	22
446	Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. Journal of Oral Pathology and Medicine, 2000, 29, 336-341.	2.7	148
447	Periodontal management of HIV-infected patients. Periodontology 2000, 2000, 23, 85-93.	13.4	23
448	Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nature Biotechnology, 2000, 18, 1060-1064.	17.5	125
449	Characterisation ofCandida albicansinfections of haematogenous and mucosal origin in mice lacking the interferon γ receptor protein. FEMS Immunology and Medical Microbiology, 2000, 27, 117-125.	2.7	4
450	Characterisation of Candida albicans infections of haematogenous and mucosal origin in mice lacking the interferon Î <sup>3</sup> receptor protein. FEMS Immunology and Medical Microbiology, 2000, 27, 117-125.	2.7	1
451	Biochemical and Immunological Characterization of MP65, a Major Mannoprotein Antigen of the Opportunistic Human Pathogen Candida albicans. Infection and Immunity, 2000, 68, 694-701.	2.2	29

#	Article	IF	CITATIONS
452	Local Anticandidal Immune Responses in a Rat Model of Vaginal Infection by and Protection against Candida albicans. Infection and Immunity, 2000, 68, 3297-3304.	2.2	78
453	In Vivo Virulence ofCandida albicansIsolates Causing Mucosal Infections in People Infected with the Human Immunodeficiency Virus. Journal of Infectious Diseases, 2000, 182, 955-959.	4.0	34
454	The significance of oral health in HIV disease. Sexually Transmitted Infections, 2000, 76, 236-243.	1.9	29
455	Growth Inhibition ofCandidaby Human Oral Epithelial Cells. Journal of Infectious Diseases, 2000, 182, 1479-1485.	4.0	85
456	Disparate Requirement for T Cells in Resistance to Mucosal and Acute Systemic Candidiasis. Infection and Immunity, 2000, 68, 2363-2365.	2.2	35
457	Generation of a Recombinant 65-Kilodalton Mannoprotein, a Major Antigen Target of Cell-Mediated Immune Response to Candida albicans. Infection and Immunity, 2000, 68, 6777-6784.	2.2	49
458	Oral Lesions in HIV/AIDS Patients Undergoing Highly Active Antiretroviral Treatment Including Protease Inhibitors: A New Face of Oral AIDS?. AIDS Patient Care and STDs, 2000, 14, 627-635.	2.5	113
459	Involvement of αvβ3 integrin-like receptor and glycosaminoglycans in Candida albicans germ tube adhesion to vitronectin and to a human endothelial cell line. Microbial Pathogenesis, 2001, 31, 159-172.	2.9	33
460	S2.3 Las candidosis orales en el paciente VIH (+): Ayer y Hoy. Gaceta Medica De Bilbao, 2001, 98, 102-103.	0.0	0
461	RecombinantStreptococcus gordoniifor Mucosal Delivery of a scFv Microbicidal Antibody. International Reviews of Immunology, 2001, 20, 275-287.	3.3	15
462	Evolution of Antifungal Susceptibility amongCandidaSpecies Isolates Recovered from Human Immunodeficiency Virus–Infected Women Receiving Fluconazole Prophylaxis. Clinical Infectious Diseases, 2001, 33, 1069-1075.	5.8	54
463	Chronic mucocutaneous candidiasis. Pediatric Infectious Disease Journal, 2001, 20, 197-206.	2.0	191
464	Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro. Immunology, 2001, 104, 455-461.	4.4	12
465	The effect of oral bacteria on Candida albicans germ-tube formationNote. Apmis, 2001, 109, 147-154.	2.0	31
466	The supportive role of complement in HIV pathogenesis. Immunological Reviews, 2001, 180, 168-176.	6.0	67
467	Oral Candida in HIV-infected heterosexuals and intravenous drug users in Thailand. Journal of Oral Pathology and Medicine, 2001, 30, 347-354.	2.7	25
468	Potential Role for a Carbohydrate Moiety in Anti- Candida Activity of Human Oral Epithelial Cells. Infection and Immunity, 2001, 69, 7091-7099.	2.2	48
469	Recovery of Candida dubliniensis and Other Yeasts from Human Immunodeficiency Virus-Associated Periodontal Lesions. Journal of Clinical Microbiology, 2001, 39, 4520-4522.	3.9	79

#	Article	IF	CITATIONS
470	Thrush and Fever as Markers of Immune Competence in the Era of Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 1311-1316.	1.1	11
471	T Cells Augment Monocyte and Neutrophil Function in Host Resistance against Oropharyngeal Candidiasis. Infection and Immunity, 2001, 69, 6110-6118.	2.2	81
472	Platelet-Activating Factor-Induced Early Activation of NF-κB Plays a Crucial Role for Organ Clearance of Candida albicans. Journal of Immunology, 2001, 166, 5139-5144.	0.8	38
473	Candidaâ€Specific Systemic Cellâ€Mediated Immune Reactivities in Human Immunodeficiency Virus–Positive Persons with Mucosal Candidiasis. Journal of Infectious Diseases, 2001, 183, 277-285.	4.0	82
474	New Model of Oropharyngeal Candidiasis in Mice. Antimicrobial Agents and Chemotherapy, 2001, 45, 3195-3197.	3.2	99
475	The Evolution ofCandidaSpecies and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV)–Seropositive and Atâ€Risk HIVâ€6eronegative Women. Journal of Infectious Diseases, 2001, 183, 286-293.	4.0	75
476	Immunomodulator Tuftsin Augments Anti-fungal Activity of Amphotericin B Against Experimental Murine Candidiasis. Journal of Drug Targeting, 2002, 10, 185-192.	4.4	20
477	THE PROTECTIVE IMMUNE RESPONSE AGAINST VAGINAL CANDIDIASIS: LESSONS LEARNED FROM CLINICAL STUDIES AND ANIMAL MODELS. International Reviews of Immunology, 2002, 21, 515-548.	3.3	25
478	Primary Role for CD4+ T Lymphocytes in Recovery from Oropharyngeal Candidiasis. Infection and Immunity, 2002, 70, 724-731.	2.2	75
479	Immune Cell-Mediated Protection against Vaginal Candidiasis: Evidence for a Major Role of Vaginal CD4+ T Cells and Possible Participation of Other Local Lymphocyte Effectors. Infection and Immunity, 2002, 70, 4791-4797.	2.2	42
480	Genetic Structure of Candida glabrata Populations in AIDS and Non-AIDS Patients. Journal of Clinical Microbiology, 2002, 40, 2199-2206.	3.9	29
481	Distinct Protective Host Defenses against oral and vaginal Candidiasis. Medical Mycology, 2002, 40, 359-375.	0.7	82
482	Ca3 Fingerprinting of Candida albicans Isolates from Human Immunodeficiency Virus-Positive and Healthy Individuals Reveals a New Clade in South Africa. Journal of Clinical Microbiology, 2002, 40, 826-836.	3.9	85
483	Evaluation of Differential Gene Expression in Fluconazole-Susceptible and -Resistant Isolates of Candida albicans by cDNA Microarray Analysis. Antimicrobial Agents and Chemotherapy, 2002, 46, 3412-3417.	3.2	93
484	Azole Susceptibility Patterns and Genetic Relationship Among Oral Candida Strains Isolated in the Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 38-44.	2.1	17
485	A Comprehensive Study ofCandidaâ€Specific Antibodies in the Saliva of Human Immunodeficiency Virus–Positive Individuals with Oropharyngeal Candidiasis. Journal of Infectious Diseases, 2002, 185, 1269-1276.	4.0	32
486	Salivary IgA and serum IgA and IgG antibodies to Candida albicans in HIV-infected subjects. International Journal of STD and AIDS, 2002, 13, 373-377.	1.1	10
487	Vaginal and Oral Epithelial Cell Anti- Candida Activity. Infection and Immunity, 2002, 70, 7081-7088.	2.2	71

#	Article	IF	CITATIONS
489	Impact of Intensified Dental Care on Outcomes in Human Immunodeficiency Virus Infection. AIDS Patient Care and STDs, 2002, 16, 479-486.	2.5	30
490	Engineered Commensal Bacteria as Delivery Systems of Anti-infective Mucosal Protectants. Biotechnology and Genetic Engineering Reviews, 2002, 19, 139-158.	6.2	5
491	Cytokine and Chemokine Production by Human Oral and Vaginal Epithelial Cells in Response to Candida albicans. Infection and Immunity, 2002, 70, 577-583.	2.2	161
492	Differences in risk factors among clinical types of oral candidiasis in the Women's Interagency HIV Study. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2002, 93, 45-55.	1.4	16
493	Treatment of oral candidiasis with methylene blue-mediated photodynamic therapy in an immunodeficient murine model. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2002, 93, 155-160.	1.4	185
494	Diversity of commensal yeasts within and among healthy hosts. Diagnostic Microbiology and Infectious Disease, 2002, 43, 19-28.	1.8	66
495	New immunotherapeutic strategies to control vaginal candidiasis. Trends in Molecular Medicine, 2002, 8, 121-126.	6.7	33
496	Antifungal drug resistance to azoles and polyenes. Lancet Infectious Diseases, The, 2002, 2, 550-563.	9.1	268
498	Effects of Psychological Stress and Alprazolam on Development of Oral Candidiasis in Rats. Vaccine Journal, 2002, 9, 852-857.	3.1	3
499	Cytokines in the oral mucosa of mice infected with Candida albicans. Oral Microbiology and Immunology, 2002, 17, 375-378.	2.8	29
500	Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. Journal of Oral Pathology and Medicine, 2002, 31, 5-10.	2.7	62
501	The epidemiology of the oral lesions of HIV infection in the developed world. Oral Diseases, 2002, 8, 34-39.	3.0	76
502	Immunity to Candida. Oral Diseases, 2002, 8, 69-75.	3.0	125
503	Prognostic significance of HIVâ€associated oral lesions and their relation to therapy. Oral Diseases, 2002, 8, 110-114.	3.0	35
504	Fungal infections associated with HIV infection. Oral Diseases, 2002, 8, 151-160.	3.0	77
505	HIV-1 and its transmembrane protein gp41 bind to differentCandidaspecies modulating adhesion. FEMS Immunology and Medical Microbiology, 2003, 37, 77-83.	2.7	9
506	Brief Exposure to Antimycotics Reduces the Extracellular Phospholipase Activity of <i>Candida albicans</i> and <i>Candida tropicalis</i> . Chemotherapy, 2003, 49, 243-247.	1.6	34
507	Longitudinal Study of MucosalCandidaSpecies Colonization and Candidiasis among Human Immunodeficiency Virus (HIV)–Seropositive and Atâ€Risk HIVâ€Seronegative Women. Journal of Infectious Diseases, 2003, 188, 118-127.	4.0	83

#	Article	IF	CITATIONS
508	Stimulation of murine macrophages by native and heat-denatured lectin from Abrus precatorius. International Immunopharmacology, 2003, 3, 375-381.	3.8	28
509	Comparison of salivary IgA and systemic IgA and IgG antibodies to Saccharomyces cerevisiae in HIV-infected subjects. International Journal of STD and AIDS, 2003, 14, 458-462.	1.1	1
510	Immunohistochemical Evaluation of T Cells in Oral Lesions from Human Immunodeficiency Virus-Positive Persons with Oropharyngeal Candidiasis. Infection and Immunity, 2003, 71, 956-963.	2.2	41
511	Efficacy of CS-758, a Novel Triazole, against Experimental Fluconazole-Resistant Oropharyngeal Candidiasis in Mice. Antimicrobial Agents and Chemotherapy, 2003, 47, 601-606.	3.2	8
512	Use of Tuftsin Bearing Nystatin Liposomes against an Isolate of Candida albicans showing Less In Vivo Susceptibility to Amphotericin B. Journal of Drug Targeting, 2003, 11, 93-99.	4.4	26
513	Multiple experimental designs to evaluate the role of T-cell-mediated immunity against experimental vaginalCandida albicansinfection. Medical Mycology, 2003, 41, 401-409.	0.7	19
514	Therapeutic Activity of an Engineered Synthetic Killer Antiidiotypic Antibody Fragment against Experimental Mucosal and Systemic Candidiasis. Infection and Immunity, 2003, 71, 6205-6212.	2.2	104
515	Genome-Wide Expression Profile Analysis Reveals Coordinately Regulated Genes Associated with Stepwise Acquisition of Azole Resistance in Candida albicans Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2003, 47, 1220-1227.	3.2	151
516	Oral Opportunistic Infections in HIV-Positive Individuals: Review and Role of Mucosal Immunity. AIDS Patient Care and STDs, 2004, 18, 443-456.	2.5	45
517	Immunopathogenesis of Oropharyngeal Candidiasis in Human Immunodeficiency Virus Infection. Clinical Microbiology Reviews, 2004, 17, 729-759.	13.6	176
518			
	Tissueâ€Associated Cytokine Expression in HIVâ€Positive Persons with Oropharyngeal Candidiasis. Journal of Infectious Diseases, 2004, 190, 605-612.	4.0	27
519	Tissueâ€Associated Cytokine Expression in HIVâ€Positive Persons with Oropharyngeal Candidiasis. Journal of Infectious Diseases, 2004, 190, 605-612. Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons. Infection and Immunity, 2004, 72, 1956-1963.	4.0 2.2	27 40
519 520	of Infectious Diseases, 2004, 190, 605-612. Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency		
	of Infectious Diseases, 2004, 190, 605-612. Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons. Infection and Immunity, 2004, 72, 1956-1963. Differential Recovery of Candida Species from Subgingival Sites in Human Immunodeficiency Virus-Positive and Healthy Children from Rio de Janeiro, Brazil. Journal of Clinical Microbiology,	2.2	40
520	of Infectious Diseases, 2004, 190, 605-612. Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons. Infection and Immunity, 2004, 72, 1956-1963. Differential Recovery of Candida Species from Subgingival Sites in Human Immunodeficiency Virus-Positive and Healthy Children from Rio de Janeiro, Brazil. Journal of Clinical Microbiology, 2004, 42, 5925-5927. Proteomic Analysis of Azole Resistance in Candida albicans Clinical Isolates. Antimicrobial Agents and	2.2 3.9	40 52
520 521	of Infectious Diseases, 2004, 190, 605-612. Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons. Infection and Immunity, 2004, 72, 1956-1963. Differential Recovery of Candida Species from Subgingival Sites in Human Immunodeficiency Virus-Positive and Healthy Children from Rio de Janeiro, Brazil. Journal of Clinical Microbiology, 2004, 42, 5925-5927. Proteomic Analysis of Azole Resistance in Candida albicans Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 2733-2735. Candida albicans and Streptococcus salivarius modulate IL-6, IL-8, and TNF-alpha expression and	2.2 3.9 3.2	40 52 60
520 521 522	of Infectious Diseases, 2004, 190, 605-612. Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons. Infection and Immunity, 2004, 72, 1956-1963. Differential Recovery of Candida Species from Subgingival Sites in Human Immunodeficiency Virus-Positive and Healthy Children from Rio de Janeiro, Brazil. Journal of Clinical Microbiology, 2004, 42, 5925-5927. Proteomic Analysis of Azole Resistance in Candida albicans Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 2733-2735. Candida albicans and Streptococcus salivarius modulate IL-6, IL-8, and TNF-alpha expression and secretion by engineered human oral mucosa cells. Cellular Microbiology, 2004, 6, 1085-1096. Regulatory networks affected by iron availability in Candida albicans. Molecular Microbiology, 2004,	2.2 3.9 3.2 2.1	40 52 60 65

#	ARTICLE	IF	CITATIONS
526	Oro-facial manifestations in paediatric HIV: a comparative study of institutionalized and hospital outpatients. Oral Diseases, 2004, 10, 13-18.	3.0	57
527	Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptibleCandida albicansinfection in temporarily neutropenic mice. FEMS Immunology and Medical Microbiology, 2004, 41, 249-258.	2.7	25
528	The Natural Course of Disease Following HIV-1 Infection in Dar es Salaam, Tanzania: A Study among Hotel Workers Relating Clinical Events to CD4+T-lymphocyte Counts. Scandinavian Journal of Infectious Diseases, 2004, 36, 466-473.	1.5	7
529	The management of opportunistic infections and cancer in HIV disease. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2004, 46, 10-20.	0.6	0
530	General Pathology of HIV Infection. , 2004, , 733-772.		0
531	Cutaneous markers of HIV infection. Clinics in Dermatology, 2004, 22, 487-498.	1.6	51
532	In vitro analyses of tissue structure and interleukin-1β expression and production by human oral mucosa in response to Candida albicans infections. Cytokine, 2004, 25, 162-171.	3.2	28
533	History and new insights into host defense against vaginal candidiasis. Trends in Microbiology, 2004, 12, 220-227.	7.7	72
534	Bone marrow colony-formation in vitro after infection of genetically defined inbred mice with Candida albicans. Microbial Pathogenesis, 2004, 36, 211-217.	2.9	6
535	Innate and Adaptive Cell-Mediated Immunity against Vaginal Candidiasis. , 2005, , 323-344.		2
536	Oral and vaginal epithelial cell antiâ€ <i>Candida</i> activity is acid labile and does not require live epithelial cells. Oral Microbiology and Immunology, 2005, 20, 199-205.	2.8	29
537	Active and passive immunization against oral Candida albicans infection in a murine model. Oral Microbiology and Immunology, 2005, 20, 376-381.	2.8	12
538	The immune response to fungal infections. British Journal of Haematology, 2005, 129, 569-582.	2.5	327
539	Colonization of Candida species in denture wearers with emphasis on HIV infection: A literature review. Journal of Prosthetic Dentistry, 2005, 93, 288-293.	2.8	60
540	Application of Deoxyribonucleic Acid Microarray Analysis to the Study of Azole Antifungal Resistance in <1>Candida albicans 1 . , 2005, 118, 045-056.		1
541	Treating Opportunistic Infections among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clinical Infectious Diseases, 2005, 40, S131-S235.	5.8	72
542	Declining Gastrointestinal Opportunistic Infections in HIV-Infected Persons: A Triumph of Science and a Challenge for Our HAARTs and Minds. American Journal of Gastroenterology, 2005, 100, 1455-1458.	0.4	12
543	Tumor Necrosis Factor Inhibition and Invasive Fungal Infections. Clinical Infectious Diseases, 2005, 41, S208-S212.	5.8	99

#	Article	IF	Citations
544	Characterization of CD8 + T Cells and Microenvironment in Oral Lesions of Human Immunodeficiency Virus-Infected Persons with Oropharyngeal Candidiasis. Infection and Immunity, 2005, 73, 3659-3667.	2.2	24
545	ADRF Research Grant Abstracts. Australian Dental Journal, 2005, 50, S3-s44.	1.5	0
548	Oral Lesions of HIV Disease and HAART in Industrialized Countries. Advances in Dental Research, 2006, 19, 57-62.	3.6	114
549	Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. Journal of Ethnopharmacology, 2006, 108, 124-132.	4.1	142
550	In vitro mechanisms of interleukin-8-mediated responses of human gingival epithelial cells to Candida albicans infection. International Journal of Medical Microbiology, 2006, 296, 301-311.	3.6	13
551	Mucocutaneous and Deeply Invasive Candidiasis. , 2006, , 926-949.		0
552	Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. , 2006, , CD003940.		23
553	(A1) Identification of Oral Health Care Needs in Children and Adults, Management of Oral Diseases. Advances in Dental Research, 2006, 19, 106-117.	3.6	15
554	Assessment of the Association Between HIV Viral Load and CD4 Cell Count on the Occurrence of Oropharyngeal Candidiasis in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 578-583.	2.1	25
555	Molecular epidemiology of long-term colonization of Candida albicans strains from HIV-infected patients. Epidemiology and Infection, 2006, 134, 265-269.	2.1	22
556	The Effect of Complete Dentures with a Metal Palate on Candida Species Growth in HIV-Infected Patients. Journal of Prosthodontics, 2006, 15, 306-315.	3.7	28
557	Chemokine receptor expression in HIV-positive persons with oropharyngeal candidiasis. Oral Diseases, 2006, 12, 493-499.	3.0	3
558	Incident HIV Infection in a High-Risk, Homosexual, Male Cohort in Rio de Janeiro, Brazil. Journal of Acquired Immune Deficiency Syndromes, 2006, 21, 408.	0.3	3
559	The Effects of HIV Infection on Oral Mucosal Immunity. Advances in Dental Research, 2006, 19, 29-35.	3.6	67
560	Characterization of the Immune Status of CD8 + T Cells in Oral Lesions of Human Immunodeficiency Virus-Infected Persons with Oropharyngeal Candidiasis. Vaccine Journal, 2006, 13, 678-683.	3.1	15
561	Neuroepidemiology of HIV/AIDS. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 85, 3-31.	1.8	1
562	Genome-Wide Expression and Location Analyses of the <i>Candida albicans</i> Tac1p Regulon. Eukaryotic Cell, 2007, 6, 2122-2138.	3.4	118
563	Potential role of high molecular weight hyaluronan in the anti-Candidaactivity of human oral epithelial cells. Medical Mycology, 2007, 45, 73-79.	0.7	18

# 564	ARTICLE Vulvovaginal candidosis. Lancet, The, 2007, 369, 1961-1971.	IF 13.7	Citations 1,050
565	A novel murine model of pharyngeal candidiasis with local symptoms characteristic of pharyngeal thrush produced by using an inhaled corticosteroid. Medical Mycology, 2007, 45, 143-148.	0.7	8
566	Treatment and Prevention of Opportunistic Infections in HIV-Infected Patients. Journal of the Korean Medical Association, 2007, 50, 324.	0.3	3
567	Impairment of p38 MAPK-mediated cytosolic phospholipase A2activation in the kidneys is associated with pathogenicity of Candida albicans. Immunology, 2007, 120, 173-181.	4.4	6
568	Fluconazole for oropharyngeal candidiasis in antiâ€HIV positive haemophiliacs. Alimentary Pharmacology and Therapeutics, 1991, 5, 199-205.	3.7	8
569	History and Update on Host Defense Against Vaginal Candidiasis. American Journal of Reproductive Immunology, 2007, 57, 2-12.	1.2	128
570	Local Th1/Th2 cytokine expression in experimental murine vaginal candidiasis. Journal of Huazhong University of Science and Technology [Medical Sciences], 2008, 28, 352-355.	1.0	8
571	Local expression of vaginal Th1 and Th2 cytokines in murine vaginal candidiasis under different immunity conditions. Journal of Huazhong University of Science and Technology [Medical Sciences], 2008, 28, 476-479.	1.0	8
572	Evaluation of enzymeâ€linked immunosorbent assays for detecting circulating antibodies to <i>Candida albicans</i> . Journal of Clinical Laboratory Analysis, 2008, 22, 234-238.	2.1	3
573	Animal models of mucosal Candida infection. FEMS Microbiology Letters, 2008, 283, 129-139.	1.8	137
574	HIV TOPIC UPDATE: Prevalence and incidence of oral lesions—the changing scene. Oral Diseases, 2000, 6, 267-273.	3.0	23
575	Antimicrobials as a contributory factor in oral candidosis – a brief overview. Oral Diseases, 2008, 14, 138-143.	3.0	67
576	Proliferative and cytotoxic responses to mannoproteins of <i>Candida albicans</i> by peripheral blood lymphocytes of HIV-infected subjects. Clinical and Experimental Immunology, 2008, 85, 485-492.	2.6	47
577	Interaction and intracellular killing of Candida albicans blastospores by human polymorphonuclear leucocytes, monocytes and monocyte-derived macrophages in aerobic and anaerobic conditions. Clinical and Experimental Immunology, 2008, 87, 316-321.	2.6	42
578	Interferon-gamma activates the oxidative killing of Candida albicans by human granulocytes. Clinical and Experimental Immunology, 2008, 91, 170-175.	2.6	26
579	Nitric oxide plays a key role in the platelet-activating factor-induced enhancement of resistance against systemic candidiasis. Immunology, 2008, 124, 428-435.	4.4	5
580	The incidence of HIV-related disease in a cohort of haemophilic men: natural history and changes since the introduction of pre-AIDS treatment. International Journal of Laboratory Hematology, 2008, 15, 241-251.	0.2	2
581	Antimicrobial effect and membraneâ€active mechanism of Urechistachykinins, neuropeptides derived from <i>Urechis unicinctus</i> . FEBS Letters, 2008, 582, 2463-2466.	2.8	31

#	Article	IF	CITATIONS
582	Yeast Infections in Immunocompromised Hosts. , 2008, , 225-232.		0
583	Human and Animal Relationships. , 2008, , .		5
584	Fungicidal effect and the mode of action of piscidin 2 derived from hybrid striped bass. Biochemical and Biophysical Research Communications, 2008, 371, 551-555.	2.1	59
585	Immunocompetent cells in oral candidiasis of HIVâ€infected patients: an immunohistochemical and electron microscopical study. Oral Diseases, 1997, 3, 99-105.	3.0	34
586	A Gain-of-Function Mutation in the Transcription Factor Upc2p Causes Upregulation of Ergosterol Biosynthesis Genes and Increased Fluconazole Resistance in a Clinical <i>Candida albicans</i> Isolate. Eukaryotic Cell, 2008, 7, 1180-1190.	3.4	203
587	Fungicidal Effect of Piscidin on Candida albicans: Pore Formation in Lipid Vesicles and Activity in Fungal Membranes. Biological and Pharmaceutical Bulletin, 2008, 31, 1906-1910.	1.4	34
588	Polysaccharide-rich fraction of Agaricus brasiliensis enhances the candidacidal activity of murine macrophages. Memorias Do Instituto Oswaldo Cruz, 2008, 103, 244-250.	1.6	12
589	Protective and pathologic immune responses against Candida albicans infection. Frontiers in Bioscience - Landmark, 2008, Volume, 3334.	3.0	31
590	Oral Complications of HIV Infection. , 2008, , 215-225.		2
591	Fungal infections in the patient with human immunodeficiency virus infection. , 2009, , 417-429.		2
592	A Novel Immune Evasion Strategy of Candida albicans: Proteolytic Cleavage of a Salivary Antimicrobial Peptide. PLoS ONE, 2009, 4, e5039.	2.5	115
593	Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. Journal of Experimental Medicine, 2009, 206, 299-311.	8.5	878
594	Case 29-2009. New England Journal of Medicine, 2009, 361, 1189-1198.	27.0	7
595	A New Experimental Model of Localized Candidosis for the Study of Antifungal Chemotherapy Ein neues Experimentalmodell der lokalisierten Candidose zum Studium der antifungalen Chemotherapie. Mycoses, 2009, 32, 398-404.	4.0	10
596	Clinical Spectrum of Oral Candidosis and its Role in HIVâ€Infected Patients. Mycoses, 1989, 32, 23-29.	4.0	6
597	Change of Causative Organisms under Antifungal Treatment in Immunosuppressed Patients with HIVâ€Infections. Mycoses, 1989, 32, 47-51.	4.0	15
598	Susceptibility to ketoconazole of Candida albicans strains from sequentially followed HIV-1 patients with recurrent oral candidosis. Mycoses, 2009, 35, 53-56.	4.0	4
599	Antifungal properties of a peptide derived from the signal peptide of the HIVâ€1 regulatory protein, Rev. FEBS Letters, 2009, 583, 1544-1547.	2.8	16

#	Article	IF	CITATIONS
600	Candida albicans adhesion to composite resin materials. Clinical Oral Investigations, 2009, 13, 293-299.	3.0	47
601	A Novel Antifungal Analog Peptide Derived from Protaetiamycine. Molecules and Cells, 2009, 28, 473-478.	2.6	7
602	Proteomic analysis of Mrr1p―and Tac1pâ€∎ssociated differential protein expression in azoleâ€resistant clinical isolates of <i>Candida albicans</i> . Proteomics - Clinical Applications, 2009, 3, 968-978.	1.6	11
603	In vitro efficacy of nisin Z against Candida albicans adhesion and transition following contact with normal human gingival cells. Journal of Applied Microbiology, 2009, 107, 1298-1307.	3.1	44
604	Oral manifestations in human immunodeficiency virus infected children in highly active antiretroviral therapy era. Journal of Oral Pathology and Medicine, 2009, 38, 613-622.	2.7	53
605	Salivary secretion, mucin concentrations and candida carriage in HIVâ€infected patients. Oral Diseases, 2009, 15, 229-234.	3.0	16
606	Farnesol promotes epithelial cell defense against Candida albicans through Toll-like receptor 2 expression, interleukin-6 and human β-defensin 2 production. Cytokine, 2009, 45, 132-140.	3.2	42
607	Associations among the use of highly active antiretroviral therapy, oral candidiasis, oral Candida species and salivary immunoglobulin A in HIV-infected children. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2009, 108, 203-210.	1.4	31
608	AIDS: otolaryngological presentation in the high-risk male homosexual. Clinical Otolaryngology, 2009, 11, 137-144.	0.0	7
609	Chronic mucocutaneous candidiasis and congenital susceptibility to Candida. Current Opinion in Allergy and Clinical Immunology, 2010, 10, 542-550.	2.3	59
610	Biofilm Related to Dental Implants. Implant Dentistry, 2010, 19, 387-393.	1.3	68
611	Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. The Cochrane Library, 2010, , CD003940.	2.8	47
612	SYK kinase signaling and the NLRP3 inflammasome in antifungal immunity. Journal of Molecular Medicine, 2010, 88, 745-752.	3.9	20
613	Adhesion of Candida albicans to various dental implant surfaces and the influence of salivary pellicle proteins. Acta Biomaterialia, 2010, 6, 2307-2313.	8.3	101
614	Ectophosphatase activity in Candida albicans influences fungal adhesion: study between HIV-positive and HIV-negative isolates. Oral Diseases, 2010, 16, 431-437.	3.0	21
615	Protection of  the oral mucosa by salivary histatin-5 against Candida albicans in an ex vivo murine model of oral infection. FEMS Yeast Research, 2010, 10, no-no.	2.3	23
616	Candida albicans cell wall components and farnesol stimulate the expression of both inflammatory and regulatory cytokines in the murine RAW264.7 macrophage cell line. FEMS Immunology and Medical Microbiology, 2010, 60, 63-73.	2.7	39
617	Mycoses and algal infections. , 2010, , 581-606.e24.		8

	CITATION	Report	
#	Article	IF	CITATIONS
618	Animal Models of Mucosal Candida Infections. Methods in Microbiology, 2010, 37, 329-352.	0.8	0
619	Effects of Psychological Stress and Fluoxetine on Development of Oral Candidiasis in Rats. Vaccine Journal, 2010, 17, 668-673.	3.1	11
620	HIV-infected patients and dermatological manifestations in a tertiary care hospital in the tribal (Bastar) region of Chhattisgarh, India between January 2006 and June 2008. Annals of Tropical Medicine and Public Health, 2010, 3, 64.	0.1	1
621	Opportunistic infections in HIV disease. British Journal of Nursing, 2010, 19, 621-627.	0.7	5
623	QSAR model for predicting the fungicidal action of 1,2,4-triazole derivatives against <i>Candida albicans</i> . Journal of Enzyme Inhibition and Medicinal Chemistry, 2010, 25, 696-701.	5.2	22
624	Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 109, 488-495.	1.4	134
625	The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans. Vaccine, 2010, 28, 614-622.	3.8	40
626	Annexin-A1 identified as the oral epithelial cell anti-Candida effector moiety. Molecular Oral Microbiology, 2010, 25, 293-304.	2.7	23
627	Photodynamic Therapy of Bacterial and Fungal Biofilm Infections. Methods in Molecular Biology, 2010, 635, 175-194.	0.9	59
629	Escheriosome mediated cytosolic delivery of Candida albicans cytosolic proteins induces enhanced cytotoxic T lymphocyte response and protective immunity. Vaccine, 2011, 29, 5424-5433.	3.8	15
630	Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal. HIV/AIDS - Research and Palliative Care, 2011, 3, 19.	0.8	13
631	Prevalence of Candida species in the oral cavity of patients with periodentitis. African Journal of Biotechnology, 2011, 10, 2987-2990.	0.6	14
632	Mucocutaneous and Deeply Invasive Candidiasis. , 2011, , 589-596.		1
633	Oral Candidiasis: Aiding in the Diagnosis of HIV—A Case Report. Case Reports in Dentistry, 2011, 2011, 1-4.	0.5	12
634	Prevalence of Oral Manifestations and Their Association with CD4/CD8 Ratio and HIV Viral Load in South India. International Journal of Dentistry, 2011, 2011, 1-8.	1.5	20
635	Host factors affecting oral candidiasis. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2011, 26, 18-21.	0.2	12
636	The pharmacokinetics of oral itraconazole in AIDS patients. Journal of Pharmacy and Pharmacology, 2011, 44, 618-619.	2.4	74
637	Candida albicans, a major human fungal pathogen. Journal of Microbiology, 2011, 49, 171-177.	2.8	398

#	Article	IF	Citations
638	Buccoadhesive Dosage Form Containing Antifungal Agent for Treating Oropharyngeal Candidiasis: A Review. Current Drug Therapy, 2011, 6, 55-64.	0.3	2
639	Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis. Current Medicinal Chemistry, 2011, 18, 2401-2419.	2.4	54
640	The Inflammasomes. , 2011, , .		9
641	The Novel Candida albicans Transporter Dur31 Is a Multi-Stage Pathogenicity Factor. PLoS Pathogens, 2012, 8, e1002592.	4.7	47
642	Gain-of-Function Mutations in <i>UPC2</i> Are a Frequent Cause of <i>ERG11</i> Upregulation in Azole-Resistant Clinical Isolates of Candida albicans. Eukaryotic Cell, 2012, 11, 1289-1299.	3.4	207
643	Association among Vitamin D, Oral Candidiasis, and Calprotectinemia in HIV. Journal of Dental Research, 2012, 91, 666-670.	5.2	23
644	Candida and candidiasis in HIV-infected patients. Aids, 2012, 26, 1457-1472.	2.2	138
645	Evaluation of protective efficacy of Spirulina platensis in Balb/C mice with candidiasis. Journal De Mycologie Medicale, 2012, 22, 329-334.	1.5	12
646	<b>Probiotics as oral health biotherapeutics</b> . Expert Opinion on Biological Therapy, 2012, 12, 1207-1220.	3.1	48
647	Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins. Cytokine, 2012, 58, 118-128.	3.2	82
648	Mendelian traits causing susceptibility to mucocutaneous fungal infections in human subjects. Journal of Allergy and Clinical Immunology, 2012, 129, 294-305.	2.9	74
649	Oral complications of HIV infection. , 2012, , 195-206.		2
650	HIV infections in otolaryngology. Medical Science Monitor, 2012, 18, RA17-RA21.	1.1	7
651	CD8 T cells and Eâ€cadherin in host responses against oropharyngeal candidiasis. Oral Diseases, 2012, 18, 153-161.	3.0	10
652	Identification by DNA microarray of genes involved in <i>Candida albicans</i> â€treated gingival epithelial cells. Journal of Oral Pathology and Medicine, 2012, 41, 769-778.	2.7	8
653	In vitro antifungal susceptibility of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia. Retrovirology, 2012, 9, .	2.0	3
654	The NK Receptor NKp30 Mediates Direct Fungal Recognition and Killing and Is Diminished in NK Cells from HIV-Infected Patients. Cell Host and Microbe, 2013, 14, 387-397.	11.0	98
655	Antifungal activity of dental resins containing amphotericin B-conjugated nanoparticles. Dental Materials, 2013, 29, e252-e262.	3.5	18

		CITATION R	EPORT	
ARTICLE			IF	Citations
	corea		2.6	96
nipponica. Biochinica Et Biophysica Acta - Biomenioranes, 2013, 1828, 1133-1138.				
	ARTICLE The antifungal activity and membrane-disruptive action of dioscin extracted from Dios nipponica. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1153-1158.	ATICLE The antifungal activity and membrane-disruptive action of dioscin extracted from Dioscore provide a disc e Biophysica Acta - Biomembranes, 2013, 1828, 1153-1158.	Article	

#	Article	IF	CITATIONS
674	Development and <i>In Vivo</i> Evaluation of a Novel Histatin-5 Bioadhesive Hydrogel Formulation against Oral Candidiasis. Antimicrobial Agents and Chemotherapy, 2016, 60, 881-889.	3.2	39
675	Oral Health. Home Health Care Management and Practice, 2017, 29, 56-59.	1.0	30
676	Comparative molecular dynamics studies of heterozygous open reading frames of DNA polymerase eta (η) in pathogenic yeast Candida albicans. Scientific Reports, 2017, 7, 41087.	3.3	7
677	Immunity to Fungal Infections. , 2017, , 35-83.		3
678	The Role of Resistance in Candida Infections: Epidemiology and Treatment. , 2017, , 1075-1097.		4
679	The Goldilocks model of immune symbiosis with Mycobacteria and Candida colonizers. Cytokine, 2017, 97, 49-65.	3.2	15
680	Commensal Fungi in Health and Disease. Cell Host and Microbe, 2017, 22, 156-165.	11.0	258
681	Relationship between the quantity of oral Candida and immunological vigor. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2017, 29, 65-70.	0.3	5
682	Direct Binding of the pH-Regulated Protein 1 (Pra1) from Candida albicans Inhibits Cytokine Secretion by Mouse CD4+ T Cells. Frontiers in Microbiology, 2017, 8, 844.	3.5	12
683	Nicotine Enhances Interspecies Relationship between <i>Streptococcus mutans</i> and <i>Candida albicans</i> . BioMed Research International, 2017, 2017, 1-9.	1.9	23
684	Chronic mucocutaneous candidiasis, a case study and literature review. Journal De Mycologie Medicale, 2018, 28, 206-210.	1.5	15
685	Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control – An update. Microbial Pathogenesis, 2018, 117, 128-138.	2.9	196
686	Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy― Infection and Immunity, 2018, 86, .	2.2	65
687	Epigenetic determinants of phenotypic plasticity in Candida albicans. Fungal Biology Reviews, 2018, 32, 10-19.	4.7	19
688	Candida psilosis Complex. , 2018, , .		1
689	Skin Diseases Associated with HIV Disease. , 2018, , 53-71.		0
690	Opportunistic infection of HIV/AIDS patients in West Papua. IOP Conference Series: Earth and Environmental Science, 2018, 125, 012062.	0.3	1
691	Disorders of the Liver Excluding Hepatitis A, B, C, D, and E. Clinical Gastroenterology, 2019, , 37-90.	0.0	0

#	Article	IF	CITATIONS
693	Commensal Candida albicans Positively Calibrates Systemic Th17 Immunological Responses. Cell Host and Microbe, 2019, 25, 404-417.e6.	11.0	151
694	Microbiome Dependent Regulation of Tregs and Th17 Cells in Mucosa. Frontiers in Immunology, 2019, 10, 426.	4.8	163
695	HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management. American Journal of Clinical Dermatology, 2019, 20, 423-442.	6.7	17
696	A novel humanized mouse model to study the function of human cutaneous memory T cells in vivo in human skin. Scientific Reports, 2020, 10, 11164.	3.3	11
697	Oral Candidiasis: A Disease of Opportunity. Journal of Fungi (Basel, Switzerland), 2020, 6, 15.	3.5	200
698	Antifungal Susceptibility Pattern of Candida Isolates: A Comparison in H.I.V. Positive and Negative Patients from A Tertiary Care Hospital of Northern India. Journal of Pure and Applied Microbiology, 2021, 15, 1230-1235.	0.9	0
699	Fungal diseases: Oral dysbiosis in susceptible hosts. Periodontology 2000, 2021, 87, 166-180.	13.4	18
700	Hairy leukoplakia. A new disease of the oral mucosa. Archives of Dermatology, 1987, 123, 585-587.	1.4	15
704	Fungal infections in the acquired immunodeficiency syndrome. Journal of Electron Microscopy Technique, 1988, 8, 115-131.	1.1	14
705	General Pathology. , 1993, , 53-98.		1
705 706	General Pathology. , 1993, , 53-98. The impact of pregnancy on HIV-related disease. , 1988, , 65-75.		1
706	The impact of pregnancy on HIV-related disease. , 1988, , 65-75.		2
706 707	The impact of pregnancy on HIV-related disease. , 1988, , 65-75. Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome. , 1989, , 284-313.		2
706 707 708	The impact of pregnancy on HIV-related disease. , 1988, , 65-75. Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome. , 1989, , 284-313. Mycoses in AIDS Patients: An Overview. , 1990, , 27-53.	1.6	2 1 7
706 707 708 709	The impact of pregnancy on HIV-related disease. , 1988, , 65-75. Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome. , 1989, , 284-313. Mycoses in AIDS Patients: An Overview. , 1990, , 27-53. Controversial Aspects of Candidiasis in the Acquired Immunodeficiency Syndrome. , 1990, , 93-100.	1.6	2 1 7 3
706 707 708 709 710	The impact of pregnancy on HIV-related disease. , 1988, , 65-75. Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome. , 1989, , 284-313. Mycoses in AIDS Patients: An Overview. , 1990, , 27-53. Controversial Aspects of Candidiasis in the Acquired Immunodeficiency Syndrome. , 1990, , 93-100. Cytokines and Anti-Fungal Immunity. Advances in Experimental Medicine and Biology, 1992, 319, 217-223. The Syndrome of Persistent Generalized Lymphadenopathy: Experience with 101 Patients. Advances in		2 1 7 3 29

#	Article	IF	CITATIONS
714	Rachen und Tonsillen. Spezielle Pathologische Anatomie, 1999, , 99-263.	0.0	1
715	Fungal Infections and AIDS. Handbook of Experimental Pharmacology, 1990, , 421-437.	1.8	3
716	Diseases Caused by Viruses. , 1991, , 13-60.		2
717	Cell-Mediated Immunity. , 1996, , 67-97.		7
718	Yeast Infections in the Immunocompromised Host. , 1996, , 117-124.		1
719	Cloning of a DNA sequence encoding a major fragment of the 47 kilodalton stress protein homologue of Candida albicans. FEMS Microbiology Letters, 1989, 60, 25-30.	1.8	51
720	AIDS and KAPOSI SARCOMA. , 1985, , 347-361.		2
721	Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection. , 2010, , 1635-1661.		1
722	General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including the Acute) Tj ETQq0 0 0 r 1705-1725.	gBT /Overl	ock 10 Tf 50 3
723	Yeast Killer Toxin-Like Antibodies in Experimental and Clinical Candidasis. , 1997, , 369-380.		1
724	Infectious diseases of the skin. , 2012, , 760-895.		12
725	Oral Manifestations Of Human Immunodeficiency Virus Infection. Otolaryngologic Clinics of North America, 1992, 25, 1211-1226.	1.1	11
726	Bacterial, Viral, Fungal, and Parasitic Infections in HIV Disease and AIDS. Dermatologic Clinics, 1991, 9, 465-492.	1.7	23
727	Acquired Immunodeficiency Syndrome. Dermatologic Clinics, 1990, 8, 771-786.	1.7	5
728	IMMUNOPATHOPHYSIOLOGY OF GASTROINTESTINAL DISEASE IN HIV INFECTION. Gastroenterology Clinics of North America, 1992, 21, 331-345.	2.2	18
729	Perspectives on Gastrointestinal Infections in AIDS. Gastroenterology Clinics of North America, 1988, 17, 451-463.	2.2	63
730	Abnormalities of the Intestinal Immune System in AIDS. Gastroenterology Clinics of North America, 1988, 17, 487-494.	2.2	15
731	Clinical Approach to Weight Loss in the Patient with HIV Infection. Gastroenterology Clinics of North America, 1988, 17, 573-586.	2.2	30

#	Article	IF	Citations
732	Infectious Diarrhea in Human Immunodeficiency Virus Infection. Gastroenterology Clinics of North America, 1988, 17, 587-598.	2.2	32
733	Odynophagia/Dysphagia in AIDS. Gastroenterology Clinics of North America, 1988, 17, 599-614.	2.2	35
734	Acquired Immunodeficiency Syndrome. Infectious Disease Clinics of North America, 1987, 1, 145-163.	5.1	1
735	Diagnosis and Management of the Oral Manifestations of HIV Infection and AIDS. Infectious Disease Clinics of North America, 1988, 2, 373-386.	5.1	22
736	Diarrhea in AIDS. Infectious Disease Clinics of North America, 1988, 2, 705-718.	5.1	10
737	Therapeutic Agents. Infectious Disease Clinics of North America, 1988, 2, 805-825.	5.1	26
738	AIDS and the Mycoses. Infectious Disease Clinics of North America, 1988, 2, 827-839.	5.1	19
739	Women and AIDS in the United States: Epidemiology, natural history, and mediating mechanisms Health Psychology, 1992, 11, 1-16.	1.6	73
741	1,25-DIHYDROXYVITAMIN D3 PROLONGS GRAFT SURVIVAL WITHOUT COMPROMISING HOST RESISTANCE TO INFECTION OR BONE MINERAL DENSITY1. Transplantation, 1998, 66, 828-831.	1.0	79
742	Evaluation of the intranasal challenge route in mice as a mucosal model for Candida albicans infection. Microbiology (United Kingdom), 1998, 144, 2291-2298.	1.8	8
743	Evidence for a more recently evolved clade within a Candida albicans North American population. Microbiology (United Kingdom), 2001, 147, 1687-1692.	1.8	28
744	AIDS: otolaryngological presentation in the high-risk male homosexual. Clinical Otolaryngology, 1986, 11, 137-144.	1.2	19
745	Site-Specific Mucosal Immunity to Fungi: Lessons Learned from Candida albicans Applied to Other Fungi. , 0, , 505-526.		1
746	Mucosal Immunity to <i>Candida albicans</i> ., 0, , 137-154.		4
747	New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents. Antimicrobial Agents and Chemotherapy, 1996, 40, 1604-1609.	3.2	14
748	Effects of Amphetamine on Development of Oral Candidiasis in Rats. Vaccine Journal, 1999, 6, 530-533.	2.6	12
749	Low Levels of Antigenic Variability in Fluconazole-Susceptible and -Resistant <i>Candida albicans</i> Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis. Vaccine Journal, 1999, 6, 665-670.	2.6	11
750	Further Characterization of Human Salivary Anticandidal Activities in a Human Immunodeficiency Virus-Positive Cohort by Use of Microassays. Vaccine Journal, 1999, 6, 851-855.	2.6	13

		CITATION REPORT		
#	Article		IF	CITATIONS
751	History of medical mycology in the united states. Clinical Microbiology Reviews, 1996,	9, 235-272.	13.6	34
752	Comparison of immunosuppressive effects of cyclosporine A in a murine model of syst and of localized thrushlike lesions. Infection and Immunity, 1989, 57, 3472-3478.	emic candidiasis	2.2	26
753	In vivo immune responses to Candida albicans modified by treatment with recombinar interferon. Infection and Immunity, 1989, 57, 1800-1808.	ıt murine gamma	2.2	51
754	Augmentation of GG2EE macrophage cell line-mediated anti-Candida activity by gamm tumor necrosis factor, and interleukin-1. Infection and Immunity, 1990, 58, 1073-1077		2.2	62
755	Mucosal and systemic candidiasis in congenitally immunodeficient mice. Infection and 58, 1093-1100.	Immunity, 1990,	2.2	148
756	Activation of the plasma kallikrein-kinin system by Candida albicans proteinase. Infecti 1990, 58, 2139-2143.	on and Immunity,	2.2	74
757	Oral and esophageal Candida albicans infection in hyposalivatory rats. Infection and In 58, 2228-2236.	ımunity, 1990,	2.2	49
758	Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels d and protective effect of exogenous administration. Infection and Immunity, 1991, 59,		2.2	90
759	Anticandidal activity of major human salivary histatins. Infection and Immunity, 1991,	59, 2549-2554.	2.2	234
760	Poly(I.C)-induced interferons enhance susceptibility of SCID mice to systemic candidia Immunity, 1992, 60, 4549-4557.	sis. Infection and	2.2	41
761	Early differential molecular response of a macrophage cell line to yeast and hyphal forr albicans. Infection and Immunity, 1992, 60, 832-837.	ns of Candida	2.2	47
762	Cytokine gene expression in human peripheral blood mononuclear cells stimulated by constituents from Candida albicans. Infection and Immunity, 1993, 61, 4105-4111.	mannoprotein	2.2	79
763	Molecular cloning and expression of a 70-kilodalton heat shock protein of Candida alb Infection and Immunity, 1995, 63, 4039-4045.	icans.	2.2	50
764	Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and Candida albicans infections. Infection and Immunity, 1995, 63, 4191-4194.	l susceptible to	2.2	42
765	Mice immunized by primary vaginal Candida albicans infection develop acquired vagina immunity. Infection and Immunity, 1995, 63, 547-553.	al mucosal	2.2	89
766	Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infection and 63, 1887-1892.	Immunity, 1995,	2.2	103
767	Circulating CD4 and CD8 T cells have little impact on host defense against experiment candidiasis. Infection and Immunity, 1995, 63, 2403-2408.	al vaginal	2.2	76
768	Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albie from oral cavities of subjects infected with human immunodeficiency virus. Infection a 1996, 64, 466-471.	cans isolates nd Immunity,	2.2	120

#	Article	IF	CITATIONS
769	Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans. Infection and Immunity, 1996, 64, 2577-2584.	2.2	73
770	T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infection and Immunity, 1996, 64, 3793-3799.	2.2	74
771	A protective role of platelet-activating factor in murine candidiasis. Infection and Immunity, 1997, 65, 1321-1326.	2.2	19
772	Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infection and Immunity, 1997, 65, 3399-3405.	2.2	182
773	Early Resistance of Interleukin-10 Knockout Mice to Acute Systemic Candidiasis. Infection and Immunity, 1999, 67, 670-674.	2.2	86
774	In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. Journal of Clinical Microbiology, 1988, 26, 2626-2631.	3.9	176
775	Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. Journal of Clinical Microbiology, 1992, 30, 3138-3145.	3.9	264
776	Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting. Journal of Clinical Microbiology, 1992, 30, 935-941.	3.9	176
777	Anticandidal activity and interleukin-1 beta and interleukin-6 production by polymorphonuclear leukocytes are preserved in subjects with AIDS. Journal of Clinical Microbiology, 1993, 31, 1354-1357.	3.9	34
778	Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients. Journal of Clinical Microbiology, 1993, 31, 2124-2133.	3.9	139
779	Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. Journal of Clinical Microbiology, 1994, 32, 59-64.	3.9	219
780	Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. Journal of Clinical Microbiology, 1995, 33, 2732-2737.	3.9	83
781	Molecular typing of Candida albicans in oral candidiasis: karyotype epidemiology with human immunodeficiency virus-seropositive patients in comparison with that with healthy carriers. Journal of Clinical Microbiology, 1995, 33, 1238-1242.	3.9	47
782	Species and Genotypic Diversities and Similarities of Pathogenic Yeasts Colonizing Women. Journal of Clinical Microbiology, 1999, 37, 3835-3843.	3.9	76
783	High Aspartyl Proteinase Production and Vaginitis in Human Immunodeficiency Virus-Infected Women. Journal of Clinical Microbiology, 1999, 37, 1376-1380.	3.9	38
784	Intestinal Lesions Associated with Disseminated Candidiasis in an Experimental Animal Model. Journal of Clinical Microbiology, 2000, 38, 2317-2323.	3.9	47
785	Macrophages in resistance to candidiasis. Microbiology and Molecular Biology Reviews, 1997, 61, 170-192.	6.6	116
786	Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiological Reviews, 1995, 59, 646-672.	10.1	135

#	Article	IF	CITATIONS
787	Heart muscle disease related to HIV infection: prognostic implications. BMJ: British Medical Journal, 1994, 309, 1605-1607.	2.3	141
788	Differential chemokine response of human monocytes to yeast and hyphal forms of <i>Candida albicans</i> and its relation to the β-1,6 glucan of the fungal cell wall. Journal of Leukocyte Biology, 2000, 68, 923-932.	3.3	47
789	Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection. PLoS Pathogens, 2016, 12, e1005663.	4.7	25
790	CandidÃase oral e leucoplasia pilosa como marcadores de progressão da infecção pelo HIV em pacientes brasileiros. Revista Brasileira De Otorrinolaringologia, 2004, 70, 310-314.	0.2	5
791	Genetic variability analysis among clinical Candida spp. isolates using random amplified polymorphic DNA. Memorias Do Instituto Oswaldo Cruz, 2004, 99, 147-152.	1.6	19
793	The effect of smoking on caries-related microorganisms. Tobacco Induced Diseases, 2019, 17, 32.	0.6	23
794	Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?. International Journal of Fertility & Sterility, 2017, 11, 134-141.	0.2	10
795	Alimentary tract biopsy lesions in the acquired immune deficiency syndrome. Pathology, 1985, 17, 181-192.	0.6	31
796	Clinical Profile of HIV/AIDS-infected Patients Admitted to a New Specialist Unit in Dhaka, Bangladesh - A Low-prevalence Country for HIV. Journal of Health, Population and Nutrition, 2011, 29, 14-9.	2.0	12
797	Balancing Treatment and Prevention: The Case of HIV/AIDS. American Journal of Applied Sciences, 2005, 2, 1380-1388.	0.2	5
798	Anti Yeast Activity of Streptomyces olivaceus Strain 115 Against Candida albicans. Journal of Applied Sciences, 2006, 6, 524-526.	0.3	1
799	Dermatological manifestations in HIV-infected patients at a tertiary care hospital in a tribal (Bastar) region of Chhattisgarh, India. Indian Journal of Dermatology, 2009, 54, 338.	0.3	35
800	Antifungal activity of plant extracts against <i>candida</i> species from oral lesions. Indian Journal of Pharmaceutical Sciences, 2008, 70, 801.	1.0	31
801	Orofacial manifestation of hematological disorders: Hemato-oncologic and immuno-deficiency disorders. Indian Journal of Dental Research, 2011, 22, 688.	0.4	18
802	Oral manifestations of HIV. Contemporary Clinical Dentistry, 2010, 1, 1.	0.7	22
803	Clinico-mycological analysis and antifungal resistance pattern in human immunodeficiency virus-associated candidiasis: An Indian perspective. Indian Journal of Sexually Transmitted Diseases and AIDS, 2018, 39, 111.	0.3	3
804	Impaired Histatin-5 Levels and Salivary Antimicrobial Activity against C.albicans in HIV Infected Individuals. Journal of AIDS & Clinical Research, 2013, 04, .	0.5	47
805	Suppression of Streptococcus mutans and Candida albicans by Probiotics:an In vitro Study. Dentistry (Sunnyvale, Calif ), 2012, 02, .	0.1	5

#	Article	IF	CITATIONS
806	The gastrointestinal and hepatic manifestations of the acquired immunodeficiency syndrome. Medical Journal of Australia, 1989, 150, 139-143.	1.7	16
807	Asymptomatic Esophageal Candidiasis in the Acquired-Immunodeficiency- Syndrome-Related Complex. Annals of Internal Medicine, 1986, 105, 145.	3.9	27
809	Diagnosis and Clinical Manifestations of HIV/AIDS. Journal of the Korean Medical Association, 2007, 50, 303.	0.3	4
810	Phagocytosis of Candida albicans by concanavalin-A activated peritoneal macrophages. Medical Mycology, 1999, 37, 195-200.	0.7	0
811	The Role of Resistance in Candida Infections: Epidemiology and Treatment. , 2009, , 931-951.		1
812	Dermatologic manifestations of HIV infection. , 2010, , 994-1001.		1
814	Fungal Infections Among Patients with AIDS. , 2011, , 525-536.		0
816	Effect of glucose supplementation on Candida albicans virulence in immunosuppressed Swiss albino mice (Mus musculus). African Journal of Microbiology Research, 2011, 5, .	0.4	1
817	Oropharyngeal Candidiasis in HIV Suspected Patients Attending State Hospital Ijebu-Ode Ogun State Nigeria. British Microbiology Research Journal, 2014, 4, 1451-1462.	0.2	0
818	Oral Manifestations of HIV Infections - A Review. Bangladesh Journal of Physiology and Pharmacology, 0, , 25-30.	0.1	0
819	Oral and maxillo-facial manifestations of acquired immunodeficiency syndrome (AIDS). Nihon Koku Geka Gakkai Zasshi, 1986, 32, 1074-1083.	0.0	0
820	Outpatient Management of Acquired Immunodeficiency Syndrome. , 1988, , 49-64.		Ο
821	The Asymptomatic HIV Antibody-Positive Patient as an In- or Outpatient in Dermatology. , 1988, , 73-79.		0
822	Dermatologische Frühsymptome bei HIV-Infektion. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1988, , 498-506.	0.0	Ο
824	Human immunodeficiency virus and acquired immune deficiency syndrome. , 1989, , 239-253.		0
825	Oral candidiasis and AIDS. , 1989, , 123-124.		1
826	AIDS: Opportunistische Pilz-Infektionen der Haut und Schleimhäte. Fortschritte Der Praktischen Dermatologie Und Venerologie, 1990, , 239-248.	0.0	0
827	Immunological Aspects of Candidosis in AIDS Patients. , 1990, , 83-91.		Ο

		CITATION RE	PORT	
#	Article		IF	CITATIONS
828	Orofacial Pain in AIDS Patients. Current Management of Pain, 1991, , 73-89.		0.1	0
829	Infections in Immunocompromised Patients. Oral and Maxillofacial Surgery Clinics of No 1991, 3, 393-403.	rth America,	1.0	1
830	Fungal Infections of the Head and Neck. Oral and Maxillofacial Surgery Clinics of North , 3, 295-309.	America, 1991,	1.0	1
831	Natural history of HIV infection. , 1992, , 1-30.			0
832	Candida. , 1992, , 205-228.			1
833	Prognostic Indicators for Progression of HIV Disease. , 1992, , 143-151.			0
834	Intracellular killing of Candida albicans by activated peritoneal macrophages. , 1992, , 5	34-539.		1
835	Acquired Immunodeficiency Syndrome. , 1992, , 859-887.			0
836	A clinical overview of opportunistic infections in patients with AIDS. , 1992, 2, 1-22.			1
837	PATHOGENESIS, NATURAL HISTORY, AND CLASSIFICATION OF HIV INFECTION. Primary Office Practice, 1992, 19, 1-17.	Care - Clinics in	1.6	3
838	Activation of plasma clotting factors by Candida albicans proteinase Japanese Journal o Biology, 1993, 35, 221-226.	of Oral	0.1	0
839	The Mucocutaneous Problems Associated with Human Immunodeficiency Virus Infectio 449-467.	n., 1994,,		0
840	Mucosal Immunopathophysiology of HIV Infection. , 1994, , 719-728.			3
841	Prognostic Indicators for Progression of HIV Disease. , 1994, , 196-205.			2
842	Malabsorption Syndromes and Intestinal Protein Loss. , 1994, , 457-491.			1
844	Gastroenterological Problems of HIV Infection and AIDS. , 1996, , 86-116.			0
845	Diagnosis and Management of Oral and Cutaneous Lesions in HIV-1 Disease. Oral and N Surgery Clinics of North America, 1998, 10, 25-44.	1axillofacial	1.0	2
846	Phagocytosis of Candida albicans by concanavalin-A activated peritoneal macrophages. Mycology, 1999, 37, 195-200.	Medical	0.7	0

ARTICLE IF CITATIONS # Specific Chromosome Alterations of Candida albicans: Mechanisms for Adaptation to Pathogenicity. 847 1 0, 197-212. Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency 848 Virus Infection. , 2015, , 1483-1502.e8. Reconstitution of the immunological defence and <i>Candida albicans</i>infection in oral mucosa of 849 0.0 0 HIV+ patients under HAART. JORDI - Journal of Oral Diagnosis, 2016, 1, . Commensal Candida Albicans Positively Calibrate Systemic Th17 Immunological Responses. SSRN Electronic Journal, O, , . Candida psilosis Complex., 2018, , 526-543. 852 0 Cutaneous Signs of AIDS. Dermatologic Clinics, 1989, 7, 571-578. 1.7 855 25â€fMycoses and algal infections. , 2010, , 489-513. 0 The Oral Clinical Features of HIV Infection. Gastroenterology Clinics of North America, 1988, 17, 2.2 535-543. Sexually Transmitted Enteric and Rectal Infections in Homosexual Men. Infectious Disease Clinics of 857 5.1 0 North Ámerica, 1987, 1, 235-251. Skin Manifestations of HIV Infection. Primary Care - Clinics in Office Practice, 1989, 16, 621-644. 1.6 Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related 904 0.3 1 Conditions. Western Journal of Medicine, 1987, 147, 460-1. Gastrointestinal manifestations of the acquired immunodeficiency syndrome. Western Journal of 0.3 Medicine, 1987, 146, 57-67. Periodontitis as an early presentation of HIV infection. Cmaj, 1991, 144, 1265-9. 906 2.0 3 The Vancouver Lymphadenopathy-AIDS Study: 5. Antecedent behavioural, clinical and laboratory findings in patients with AIDS and HIV-seropositive controls. Cmaj, 1986, 135, 881-7. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized 908 89 2.6 lymphadenopathy. Clinical and Experimental Immunology, 1987, 68, 479-87. Early Clinical Signs and Symptoms of HIV Infection: Delaying progression to AIDS. Canadian Family Physician, 1992, 38, 1401-10. 909 Acquired immune deficiency syndrome in Northern Ireland. Ulster Medical Journal, 1986, 55, 80-3. 910 0.2 1 Epidemic human immunodeficiency virus (HIV) infection among intravenous drug users (IVDU). Yale Journal of Biology and Medicine, 1987, 60, 545-67.

#	Article	IF	CITATIONS
912	HIV enteropathya challenge in diagnosis and management. Journal of the National Medical Association, 1994, 86, 347-51.	0.8	0
913	Prevalence of oral lesions in patients with AIDS: a systematic review and meta-analysis. Evidence-Based Dentistry, 2021, , .	0.8	2
914	Epidemiology and Prevalence of Oral Candidiasis in HIV Patients From Chad in the Post-HAART Era. Frontiers in Microbiology, 2022, 13, 844069.	3.5	20
915	Inhibitory effects of different fractions separated from standardized extract of Myrtus communis L. against nystatin-susceptible and nystatin-resistant Candida albicans isolated from HIV positive patients. Heliyon, 2022, 8, e09073.	3.2	5
917	Quantification of Oral Candidal Carriage Rate and Prevalence of Oral Candidal Species in HIV Patients with and Without Highly Active Antiretroviral Therapy Journal of Microscopy and Ultrastructure, 2021, 9, 145-153.	0.4	2
918	Raman Spectroscopy of Oral Candida Species: Molecular-Scale Analyses, Chemometrics, and Barcode Identification. International Journal of Molecular Sciences, 2022, 23, 5359.	4.1	15
919	ORAL MANIFESTATIONS OF' HUMAN IMMUNODEFICIENCY VIRUS INFECTION. Dental Clinics of North America, 1993, 37, 21-32.	1.8	34
920	ORAL MANIFESTATIONS OF INFECTIOUS DISEASES. Dental Clinics of North America, 1996, 40, 395-423.	1.8	37
921	DIAGNOSTIC CONSIDERATIONS FOR THE MEDICALLY COMPLEX PATIENT. Dental Clinics of North America, 1992, 36, 841-855.	1.8	0
922	Manifestaciones mucocutÃ;neas y su relación con el recuento de linfocitos T CD4 en pacientes infectados con el virus de inmunodeficiencia humana hospitalizados en MedellÃn, Colombia. Biomedica, 2022, 42, 278-289.	0.7	2
923	Gastrointestinal Manifestations of the Acquired Immunodeficiency Syndrome. Nursing Clinics of North America, 1989, 24, 395-406.	1.5	10
924	WOMEN AND HIV: A Review of Current Epidemiology, Gynecologic Manifestations, and Perinatal Transmission. Primary Care - Clinics in Office Practice, 1997, 24, 617-641.	1.6	3
925	Acquired Immunodeficiency Syndrome and Disease of the Gastrointestinal Tract. Immunology and Allergy Clinics of North America, 1988, 8, 451-467.	1.9	2
926	Lantibiotics in antifungal therapy: a futuristic approach. , 2023, , 205-220.		0
927	Gastrointestinal Disease in AIDS. , 1986, 6, 519-541.		5
928	The Spectrum of Human Immunodeficiency Virus (HIV) Infection: Routes of Infection, Natural History, Prevention and Treatment. , 1986, 6, 467-488.		2
930	Treatment of Fungal Infections in Patients Infected with the Human Immunodeficiency Virus. Pharmacotherapy, 1990, 10, .	2.6	0
931	Generation of a highly immunogenic recombinant enolase of the human opportunistic pathogen <i>Candida albicans</i> . Biotechnology and Applied Biochemistry, 1999, 29, 223-227.	3.1	5

#	Article	IF	CITATIONS
932	New Insights Into Candidal Infections. Advances in Pediatrics, 1996, 43, 209-230.	1.4	0
933	Ascomycetes yeasts: The hidden part of human microbiome. WIREs Mechanisms of Disease, 2024, 16, .	3.3	0
934	Oesophageal Mycosis: Epidemiological and Clinical Aspects and Risk Factors for Occurrence in the Digestive Endoscopy Unit of the Donka National Hospital, Conakry CHU. Open Journal of Gastroenterology, 2024, 14, 31-40.	0.1	0